Document:

Exhibit
10.50

 

Portions
of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm
to Harrow Health, Inc. if publicly disclosed.

 

December
6, 2021

 

VIA
EMAIL

 

Imprimis
Rx, LLC

12264
El Camino Real

Suite
350

San
Diego, California 92130

Attn:
John Saharek

Email:

 

	Re:	Commercial
                                            Alliance Agreement: Expansion of Imprimis Responsibilities

 

Dear
John:

 

EyePoint
Pharmaceuticals, Inc. (“EyePoint”) and ImprimisRx, LLC (“Imprimis”) entered into a Commercial Alliance
Agreement effective as of August 1, 2020, as modified by the Letter Agreement dated November 12, 2020 (collectively, the “Agreement”).
Capitalized terms used but not defined in this letter have their respective meanings set forth in the Agreement. All changes to the Agreement
described below shall be effective as of January 1, 2022 (the “Expansion Effective Date”). For good and valuable consideration,
the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

Changes
to the Agreement:

 

Notwithstanding
anything to the contrary in the Agreement, the terms of this letter describe certain provisional changes and other amendments in and
to the responsibilities and obligations of the parties that will be effective from the Expansion Effective Date through December 31,
2023 (the “Expansion Term”), unless the Expansion Term is shortened or extended by mutual agreement, or as described
below.

 

	 	●	To
    provide for commercial continuity in the event the pass-through period lapses and is granted during a subsequent CMS cycle, Section
    13.3 will be replaced with the following text:
	 	 	 
	 	●	End
    of Pass-Through Payment Status. If Pass-Through Payment Status ceases for a period of not less than six (6) months, then either
    Party may terminate this Agreement by providing thirty (30) days’ prior written notice of termination to the other Party. 

 

    	1

     

    

 

	 	●	During
    the Expansion Term:
	 	 	 
	 	●	Imprimis
    assumes the following responsibilities and obligations, and will indemnify and hold EyePoint harmless, pursuant to Section 12.2 of
    the Agreement, from and against all Liabilities resulting from any Third-Party Claim resulting from any of the following:

 

	 	○	Full
    responsibility for all current Dexycu Sales, Marketing and Medical Science Liaison (MSL) functions, including compliance with all
    applicable laws or regulations related to such responsibilities

 

	 	■	Exception:
    EyePoint marketing and MSL personnel currently dedicated to Dexycu will remain with EyePoint in new roles, but will provide 90 days
    of transition services from the commencement of the Expansion Term. Imprimis shall pay EyePoint for such transition services at EyePoint’s
    cost.

 

	 	○	Imprimis
    will offer full-time employment to these current EyePoint personnel, as of the Expansion Effective Date, on equivalent or better
    salary, bonus, equity opportunities:

 

	 	■	[***]

 

	 	○	Imprimis
    will also assume full responsibility and all associated costs for the following functions pertaining to Dexycu:

 

	 	■	Promotional
    Review Committee (PRC): Imprimis to work with its existing firm, rather than EyePoint’s consultant
	 	■	Compliance
    (Sunshine Act, SOPs, training, etc.): Imprimis to engage EyePoint’s current consultant at G&M Healthcare
	 	■	Speaker
    Programs
	 	■	Trade
    Shows
	 	■	Customer
    Training

 

	 	●	EyePoint
    will provide transition services to Imprimis pertaining to the above responsibilities for a mutually agreed upon period and rate
    of compensation to EyePoint. 
	 	 	 
	 	●	In
    addition, EyePoint shall provide the following services to Imprimis, at cost (payable by Imprimis to EyePoint):

 

	 	○	Field
    Reimbursement and Government Pricing Management
	 	○	HUB
    Management (as required)
	 	○	Safety
    and Pharmacovigilance
	 	○	Information
    Technology support (as required)
	 	○	Distribution
    Management

 

    	2

     

    

 

 

	 	●	EyePoint
    shall retain the following responsibilities and obligations, and will indemnify and hold Imprimis harmless, pursuant to Section 12.1
    of the Agreement, from and against all Liabilities resulting from any Third-Party Claim resulting from any of the following:

 

	 	○	Manufacturing,
    sterilization, packaging
	 	○	Product
    design
	 	○	Product
    labeling
	 	○	Engagement
    of pass-through extension consultants and counsel

 

	 	■	EyePoint
    will continue to pursue pass-through extension for Dexycu in a manner consistent with its good faith efforts to secure pass-through
    extension to date

 

	 	○	Engagement
    of physician consultants
	 	○	Research
    & Development
	 	○	Reimbursement
    management
	 	○	Required
    Clinical Trials

 

	 	■	Including,
    but not limited to, the FDA-required pediatric study

 

	 	○	Quality
	 	○	Regulatory
	 	○	Intellectual
    Property protection
	 	○	Fulfillment
    of obligations to licensees outside of the Territory, including but not limited to, Ocumension
	 	○	A
    summary of material items related to these activities will be reported through the Commercialization Committee on a monthly basis
    with a particular focus related to pass-through extension and label expansion activity (e.g., sNDA)

 

	 	●	Sales-related
    specifics during the Expansion Term:

 

	 	○	The
    term “Customers” shall mean, collectively, all customers for the Product in the Territory.
	 	 	 
	 	○	The
    [***] Remittance Percentage shall apply to Net Sales of the Product in the Territory
	 	 	 
	 	○	Imprimis
    shall be permitted to negotiate GPO, private equity, and related contracts, subject to the following requirements:

 

	 	■	All
    such contracts shall only be effective during the Expansion Term; and
	 	 	 
	 	■	All
    contract terms that could affect ASP, such as rebates, volume discounts, assurance of commercial and Med Advantage carrier reimbursement,
    bundling with other products or services, etc., must be approved by EyePoint in writing in advance if such terms fall outside the
    parameters set forth in Exhibit A attached to this letter.

 

    	3

     

    

 

	 	○	The
    Commercialization Committee shall continue to meet monthly, primarily to review and, if applicable, approve contract terms with key
    accounts and other matters as needed.
	 	 	 
	 	○	Audit
    Rights: In addition to the rights specified in Section 8.6 of the Agreement, EyePoint or its designee shall have the right, but not
    the obligation, during the Expansion Term and for the remainder of the Term:

 

	 	■	To
    observe directly through field rides the performance of Imprimis personnel and 1099 reps in the field, to ensure compliance with
    the Agreement and with the terms of this Letter.

 

	 	●	Mandatory
    Milestones and Downside Protection for EyePoint; Early Termination of Expansion Term

 

	 	○	Imprimis
    shall achieve quarterly Customer demand milestones for the Product of at least [***] Dexycu units (“Minimum Quarterly Units”
    or “MQUs”).
	 	 	 
	 	○	Imprimis
    shall pay to EyePoint an annually-determined per-unit penalty for Customer demand units that fall below the MQUs, as measured on
    January 31, 2023 and January 31, 2024, respectively, and in the amounts set forth on Exhibit B attached hereto; provided however,
    in any event, such penalty amount shall not exceed total commissions payable by EyePoint to Imprimis for Customer demand achieved
    during 2022 and 2023, respectively. 
	 	 	 
	 	○	EyePoint
    shall have the right, but not the obligation, to terminate the Expansion Term upon 90-days written notice to Imprimis, if Imprimis
    fails to achieve the MQUs or to pay any applicable penalties set forth in Exhibit B.
	 	 	 
	 	○	Imprimis
    shall have the right, but not the obligation to terminate the Expansion Term upon 30 days written notice if (i) a proposed or final
    Hospital Outpatient Prospective Payment System (HOPPS) rule issued from CMS during calendar year 2022 does not contain an
    extension of the Pass-Through Payment Period for Dexycu beyond December 31, 2022, and (ii) EyePoint has not otherwise waived the
    MQU for a quarterly period inclusive of or following the date of the proposed or final HOPPS rule described in (i) above.

 

Additional
Terms:

 

This
letter will be governed by and construed under and in accordance with the laws of the State of Delaware, without regard to the conflicts
of laws principles thereof.

 

Unless
expressly modified by this Letter, all terms and conditions set forth in the Agreement shall remain in full force and effect for the
duration of the Section 13.1 Term.

 

If
the foregoing is acceptable to you, please sign and return one fully-executed copy of this letter to us at your earliest convenience,
which shall evidence your acknowledgement and acceptance thereto. This letter may be executed in counterparts, each of which shall be
deemed to be an original and together shall be deemed to be one and the same document.

 

[Signature
Page Follows.]

 

    	4

     

    

 

	 	Very truly yours,
	 	 	 
	 	EyePoint Pharmaceuticals, Inc.
	 	 	 
	 	By:	/s/
    Nancy Lurker
	 	 	
	 	Name:	Nancy
    Lurker
	 	  	 
	 	Title:	President
    & CEO

 

	Agreed to and accepted:	 
	 	 	 
	ImprimisRx, LLC	 
	 	 	 
	By:	/s/
    John Saharek 	 
	 	 	 
	Name:	John
    Saharek 	 
	 	 	 
	Title:	President
    	 
	 	 	 
	Date:	December
    6, 2021 	 

 

    	5

     

    

 

EXHIBIT
A

 

Rebate/Volume
Discount Limits for 2022

[***]

 

    	6

     

    

 

EXHIBIT
B

 

Downside
Protection Penalties

(EXAMPLE)

[***]

 

    	7Exhibit
10.51

 

ASSET
PURCHASE AGREEMENT

 

by
and between

 

NOVARTIS
TECHNOLOGY LLC and NOVARTIS OPHTHALMICS AG

 

and

 

HARROW
HEALTH, INC.

 

DATED
AS OF 17 DECEMBER, 2021

 

    	 

     

    

 

TABLE OF CONTENTS

 

	 	Page
	 	 
	ARTICLE
    1 DEFINITIONS	1
	 	 	 
	1.1	Definitions	1
	1.2	Other
    Capitalized Terms	9
	1.3	Interpretive
    Provisions	9
	 	 	 
	ARTICLE
    2 SALE AND TRANSFER OF ASSETS	10
	 	 	 
	2.1	Purchase
    and Sale of Transferred Assets.	10
	2.2	No
    Transfer of Certain Assets	12
	2.3	Risk
    of Loss	13
	 	 	 
	ARTICLE
    3 ASSUMED LIABILITIES AND EXCLUDED LIABILITIES	13
	 	 	 
	3.1	Assignment
    and Assumption of Assumed Liabilities	13
	3.2	Excluded
    Liabilities	13
	 	 	 
	ARTICLE
    4 GRANT OF LICENSES	14
	 	 	 
	4.1	Grant
    of Licenses	14
	4.2	Reservation
    of Rights	14
	4.3	Restriction
    to Territory	14
	 	 	 
	ARTICLE
    5 PAYMENTS	15
	 	 	 
	5.1	Consideration	15
	5.2	Taxes	16
	 	 	 
	ARTICLE
    6 THE CLOSING	16
	 	 	 
	6.1	Closing	16
	6.2	Deliverables	16
	 	 	 
	ARTICLE
    7 REPRESENTATIONS AND WARRANTIES OF NOVARTIS	17
	 	 	 
	7.1	Organization;
    Qualification	17
	7.2	Authority;
    Enforceability	17
	7.3	No
    Violations; Consents	18
	7.4	Litigation	18
	7.5	Debarred
    Personnel	18
	7.6	Title
    to Assets	18
	7.7	Intellectual
    Property	18
	7.8	Compliance
    with Applicable Law	19
	7.9	Exclusivity
    of Representations	20
	 	 	 
	ARTICLE
    8 REPRESENTATIONS AND WARRANTIES OF PURCHASER	20
	 	 	 
	8.1	Organization;
    Qualification	20
	8.2	Authority;
    Enforceability	20
	8.3	No
    Violations; Consents	21

 

    	ii

     

    

 

	8.4	Litigation	21
	8.5	Debarred
    Personnel	21
	8.6	Availability
    of Funds	21
	8.7	Compliance
    with Applicable Law	22
	8.8	No
    Knowledge of Misrepresentation or Omission	22
	8.9	Independent
    Assessment; No Inducement or Reliance	22
	8.10	Exclusivity
    of Representations	23
	 	 	 
	ARTICLE
    9 COVENANTS	23
	 	 	 
	9.1	Confidentiality	23
	9.2	Press
    Releases	23
	9.3	Novartis
    Names and Marks	23
	9.4	Pharmacovigilance
    Agreement; Other Obligations	24
	9.5	Transferring
    of Product NDAs	24
	9.6	Maintenance
    of Product NDAs Pending Notification of Transfer to the FDA	24
	9.7	Recordations
    and Filings	24
	9.8	Authorized
    generic agreement	25
	9.9	Accounts
    Receivable and Payable	25
	9.10	Wrong
    Pockets	25
	9.11	Transfer
    of Books and Records	26
	9.12	Preservation
    of Records; Novartis’ Access	26
	9.13	Cooperation
    in Litigation and Investigations	26
	9.14	Further
    Assurances	27
	 	 	 
	ARTICLE
    10 INDEMNIFICATION; SURVIVAL	27
	 	 	 
	10.1	Survival	27
	10.2	Indemnification
    by Novartis	28
	10.3	Indemnification
    by Purchaser	28
	10.4	Limitations
    on Amounts of Losses	28
	10.5	Other
    Limitations on Indemnification	29
	10.6	Procedures.	29
	10.7	Tax
    Treatment	31
	10.8	Exclusive
    Remedy	31
	10.9	No
    Setoff Rights	31
	 	 	 
	ARTICLE
    11 MISCELLANEOUS	31
	 	 	 
	11.1	Expenses	31
	11.2	Waiver
    and Amendment	31
	11.3	Entire
    Agreement	31
	11.4	Headings	32
	11.5	Notices	32
	11.6	Binding
    Effect; Assignment	33
	11.7	No
    Third Party Beneficiary	33
	11.8	Counterparts	33
	11.9	Force
    Majeure	33
	11.10	Governing
    Law and Jurisdiction	33
	11.11	WAIVER
    OF JURY TRIAL	34
	11.12	Severability	34
	11.13	Specific
    Performance	34
	11.14	Relationship
    of the Parties	34
	11.15	Extension
    to Affiliates	34
	11.16	English
    Language	35
	11.17	Construction	35
	11.18	No
    Recourse Against Nonparty Affiliates	35
	11.19	Novartis
    Disclosure Schedule	35

 

    	iii

     

    

 

List
of Annexes

 

	Annex
    1.1(a)	–	Domain
    Names
	Annex
    1.1(b)	–	Drug
    Substance
	Annex
    1.1(c)	–	Purchaser
    Knowledge Parties
	Annex
    1.1(d)	–	Novartis
    Knowledge Parties
	Annex
    1.1(e)	–	Trademarks
	Annex
    1.1(f)	–	Product
    NDAs
	Annex
    5.1(c)	–	Purchase
    Price Allocation

 

List
of Exhibits

 

	Exhibit
    A	–	Bill
    of Sale & Assignment and Assumption Agreement
	Exhibit
    B	–	Press
    Release

 

List
of Simultaneously Executed Agreements

 

Alcon
Sublicense Agreement

Commercial
Agreement

Domain
Name Assignment Agreement

License
Agreement

Patent
Assignment Agreement

Supply
Agreement

Trademark
Assignment Agreement

Transition
Services Agreement

 

    	iv

     

    

 

ASSET
PURCHASE AGREEMENT

 

This
ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of this 17 day of December, 2021, by and between Novartis
Technology LLC (“NTLLC”), a limited liability company organized under the laws of the State of Delaware and having
its principal place of business at One Health Plaza, East Hanover, New Jersey, 07936, Novartis Ophthalmics AG, a company organized under
the laws of Switzerland and having its principal place of business at Rue Louis-d’Affry 6, 1700 Fribourg, Switzerland (“NOAG”
and NOAG and NTLLC being collectively referred to as “Novartis”) and Harrow Health, Inc., a corporation formed under
the laws of Delaware and located at 102 Woodmont Blvd. Suite 610, Nashville, TN 37205 (“Purchaser”). Novartis and
Purchaser are each referred to individually as a “Party” and together as the “Parties”.

 

RECITALS

 

WHEREAS,
Novartis and its Affiliates sell, market, distribute, manufacture, and otherwise commercialize, by themselves or through Third Parties,
the Drug Substances and the Products in the Territory;

 

WHEREAS,
Novartis desires to sell, transfer, assign, convey and deliver to Purchaser, and Purchaser desires to purchase from Novartis, the Transferred
Assets, and Novartis desires to assign to Purchaser and Purchaser desires to assume from Novartis the Assumed Liabilities, all upon and
subject to the conditions hereinafter specified;

 

WHEREAS,
Novartis and/or its Affiliates own intellectual property and technology related to the Drug Substances and the Products in the Territory,
separate from the Transferred Assets, and they are willing to grant Purchaser certain rights to such intellectual property and technology
as set forth herein and in the License Agreement; and

 

WHEREAS,
in connection with the transactions contemplated hereby, the Parties and/or their respective Affiliates desire to enter into the Ancillary
Agreements, and Novartis is willing to provide certain services involving the supply of the Products in the Territory for a transition
period as set forth in this Agreement and the Supply Agreement.

 

NOW
THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants, and agreements contained
herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as
follows:

 

ARTICLE
1

DEFINITIONS

 

1.1
Definitions. The following terms, whenever used herein, shall have the following meanings for all purposes of this Agreement.

 

“Act”
means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.

 

    	1

     

    

 

“Adverse
Event” means any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product
and that does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended
sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether
or not related to the medicinal product.

 

“Affiliate”
means, with respect to a Party, any Person that, directly or indirectly, controls, is controlled by, or is under common control with
that Party. For the purpose of this definition, “control” or “controlled” means, direct or indirect, ownership
of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation or
fifty percent (50%) or more of the equity interest in the case of any other type of legal entity; status as a general partner in any
partnership; or any other arrangement whereby the entity or Person controls or has the right to control the board of directors or equivalent
governing body of a corporation or other entity or the ability to cause the direction of the management or policies of a corporation
or other entity. The Parties acknowledge that in the case of entities organized under the laws of certain countries where the maximum
percentage ownership permitted by Law for a foreign investor is less than fifty percent (50%), and in such cases such lower percentage
shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and
policies of such entity while owning, directly or indirectly, such lower percentage.

 

“Alcon
Sublicense Agreement” means the Alcon Sublicense Agreement entered into between Purchaser and Novartis (or one or more of its
Affiliates) on the date hereof and effective as of the Closing Date.

 

“Ancillary
Agreements” means the Alcon Sublicense Agreement, Bill of Sale & Assignment and Assumption Agreement, the Commercial Agreement,
the Domain Name Assignment Agreement, the License Agreement, the Patent Assignment Agreement, the Supply Agreement, the Trademark Assignment
Agreement, the Transition Services Agreement and each other agreement or certificate to be delivered by any Party hereto at the Closing
contemplated hereby.

 

“Antitrust
Laws” means any Laws applicable to Novartis and Purchaser under any applicable jurisdiction that are designed or intended to
prohibit, restrict, or regulate actions having the purpose or effect of monopolization or restraint of trade.

 

“Authorization”
means any consent, authorization, approval, order, license, certification, or permit of or from, or declaration or filing with, any Governmental
Entity, including any required filing with any Governmental Entity and the subsequent expirations of any required waiting period under
any Antitrust Law.

 

“Bill
of Sale & Assignment and Assumption Agreement” means the Bill of Sale & Assignment and Assumption Agreement entered
into between Purchaser and Novartis (or one or more of its Affiliates) as of the Closing Date in the form attached as Exhibit A.

 

“Business
Day” means a day (other than a Saturday, Sunday or a public holiday) on which the banks are open for business in Basel, Switzerland
and New York, New York, United States.

 

“Closing
Date” means the date on which Closing actually occurs.

 

    	2

     

    

 

“Commercial
Agreement” means the Commercial Agreement entered into between Purchaser and Novartis (or one or more of its Affiliates) on
the date hereof and effective as of the Closing Date.

 

“Commercial
Information” means marketing, advertising, and promotional and similar information, including sales and customer information,
that is existing, owned, and used by Novartis and in Novartis’ possession as of the Closing Date, for the commercialization of
any of the Products in the Territory, excluding (a) the Novartis Names and Marks, (b) any information that cannot be transferred or otherwise
disclosed pursuant to applicable Law, and (c) any information that is covered by confidentiality obligations in respect of a Third Party
for which Novartis has not obtained such Third Party’s consent (provided however that Novartis shall use commercially reasonable
efforts to obtain the consent of any relevant Third Party).

 

“Confidentiality
Agreement” means that certain confidentiality agreement entered into between Novartis and Purchaser or any of their respective
Affiliates on 17 August 2020, as amended from time to time.

 

“Domain
Name Assignment Agreement” means the Domain Name Assignment Agreement entered into between Purchaser and Novartis (or one or
more of its Affiliates) on the date hereof and effective as of the Closing Date.

 

“Drug
Substance” means:

 

(a)
in respect of Maxitrol, the active pharmaceutical ingredients dexamethasone, neomycin sulfate and polymyxin B sulfate,

 

(b)
in respect of Iopidine, the active pharmaceutical ingredient apraclonidine hydrochloride, and

 

(c)
in respect of Moxeza, the active pharmaceutical ingredient moxifloxacin,

 

in
each case having the chemical structure set forth in Annex 1.1(b).

 

“Encumbrance”
means any encumbrance, claim, charge, hypothecation, lien, license, mortgage, pledge, easement, defect in title, restrictive covenant,
option, right of first refusal, or security interest of any kind.

 

“Excluded
Agreements” means all agreements of Novartis or its Affiliates.

 

“Ex-Territory
Product” means each branded product containing any Drug Substance, which is marketed and sold by Novartis, its Affiliates,
any of their service providers and/or Other Partners under trademarks, which include the tradenames MAXITROL, IOPIDINE or MOXEZA and
an equivalent of an NDA in any jurisdiction outside of the United States for such branded products outside the Territory.

 

“FDA”
means the United States Food and Drug Administration.

 

“Force
Majeure” means any event which is beyond the reasonable control of the Party affected, including the following events: earthquake,
storm, flood, fire or other acts of nature, epidemic, war, riot, public disturbance, strike or lockouts, government actions, terrorist
attack, or the like.

 

    	3

     

    

 

“Fraud”
means actual and intentional fraud with respect to the making of the representations and warranties pursuant to ARTICLE 7 or ARTICLE
8 (as applicable), provided that such actual and intentional fraud shall only be deemed to exist if, and the Party asserting
or relying on the occurrence of such actual and intentional fraud shall satisfy its burden of proof of establishing by a preponderance
of the evidence that, any of the individuals identified in Annex 1.1(c) (in the case of an assertion by Purchaser) or any of the
individuals identified in Annex 1.1(d) (in the case of an assertion by Novartis), or their predecessors, had actual knowledge
(as opposed to imputed or constructive knowledge) that the representations and warranties made by a Party pursuant to, in the case of
Novartis, ARTICLE 7, or, in the case of Purchaser, ARTICLE 8, were actually breached when made, and that such breach was
committed with the express intention and purpose that the other Party be deceived and rely thereon to its detriment.

 

“Governmental
Entity” means any court, agency, authority, department, legislative or regulatory body, or other instrumentality of any government
or country or of any national, federal, state, provincial, regional, county, city, or other political subdivision of any such government
or any supranational organization of which any such country is a member or quasi-governmental authority or self-regulatory organization
of competent authority.

 

“Inventory”
means all stock of Materials, Drug Substance, and/or Products that are solely maintained, held, or stored by or on behalf of Novartis
or its Affiliates for the sale, distribution, and commercialization of the Products as of the Closing Date.

 

“Iopidine”
means the pharmaceutical product containing the active ingredient apraclonidine hydrochloride sold under the brand name Iopidine as marketed
and sold by Novartis and/or its Affiliates under the relevant Product NDAs in the Territory as of the date hereof.

 

“Know-How”
means all existing and available technical information, know-how, and data, including inventions (whether patentable or not), discoveries,
trade secrets, specifications, instructions, processes, formulae, materials, and other technology related to the Products or to their
manufacture, registration, use, or commercialization and including all biological, chemical, pharmacological, biochemical, toxicological,
pharmaceutical, physical, safety, quality control, preclinical, and clinical data relating to the Products in the Territory, and that
is in existence, reasonably accessible, owned by, and available to Novartis and/or its Affiliates on the Closing Date, but specifically
excluding NDA Data, Commercial Information, and Medical Information.

 

“Knowledge”
means, with respect to Purchaser, the actual knowledge of the individuals listed in Annex 1.1(c), and with respect to Novartis,
the actual knowledge of any of the employees of Novartis listed in Annex 1.1(d) as well as the knowledge that any such individual
would have obtained through due inquiry into the relevant matter.

 

“Law”
means any statute, law, treaty, judgment, ordinance, requirement, decree, regulatory rule, administrative interpretation, code, order,
or other requirement having the force of law of any Governmental Entity.

 

    	4

     

    

 

“Liabilities”
means any and all debts, liabilities, expenses, and obligations, of any nature or kind whether accrued or fixed, absolute or contingent,
matured or unmatured, or determined or determinable, including product liability, and, more generally, any liability arising under any
Law, action, or governmental order, injunction, or decree and any liability arising under any contract or undertaking.

 

“License
Agreement” means the License Agreement entered into between Purchaser and Novartis (or one or more of its Affiliates) on the
date hereof and effective as of the Closing Date.

 

“Licensed
IP” means the Licensed Trademarks and the Know-How other than the Transferred IP.

 

“Licensed
Trademarks” means those registered trademarks and pending trademark applications in the Territory listed in Annex 1.1(e)
under the heading “Licensed Trademarks”, including all goodwill associated therewith.

 

“Loss”
means any and all direct and foreseeable damage, loss, liability, and expenses actually incurred by a Party, including reasonable attorney’s
fees and expenses in connection with any action, suit, or proceeding, whether involving a Third-Party Claim or a claim solely between
the Parties; provided, however, Losses shall not include any special, punitive, consequential, or indirect damages or any
similar damages or damages based upon diminution in value or any valuation multiplier unless payable to a Third Party as a result of
a Third-Party Claim.

 

“Material
Adverse Effect” means a change, effect, event, occurrence, or development that, individually or in the aggregate, is, or could
reasonably be expected to become, materially adverse to the condition of the Transferred Assets and the Licensed IP, taken as a whole,
or to the Purchased Business or the ability of Novartis to consummate the transactions contemplated hereby on a timely basis, or to any
of the Product NDAs; provided, however, that none of the following changes, effects, events, occurrences, or developments
shall be deemed either alone or in combination to constitute, and none of following shall be taken into account in determining whether
there has been or will be, a Material Adverse Effect: (a) any adverse effect, event, occurrence, or development attributable to changes
in conditions generally affecting (i) the pharmaceutical industry or (ii) the economy, financial, or securities markets or political,
legislative, or regulatory conditions, taken as a whole, except in the case of effects referenced in clauses (i) or (ii), for effects
that, taken as a whole, disproportionately impact the Products, as compared to similar pharmaceutical products, (b) any adverse effect
caused by the entry into this Agreement, announcement of this Agreement, and the pendency of the transactions contemplated hereby, (c)
any adverse effect due to acts of war, armed hostility, or terrorism, (d) any adverse effect due to actions or inactions taken by Novartis
or any of its Affiliates in the performance of its obligations under this Agreement, (e) any adverse effect due to any claims or actions
or government or other investigations pending as of the date hereof, disclosed in Section 1.1(a) of the Novartis Disclosure Schedule,
or (f) any effect or change resulting from any action by, the identity of, or any facts or circumstances directly related to Purchaser.

 

    	5

     

    

 

“Materials”
means any materials or components used in the manufacture of any of the Products, including: (a) raw ingredients, (b) intermediates,
(c) excipients, (d) processing aids, (e) active ingredients, including the Drug Substance, (f) bulk drug product, and (g) packaging and
labelling materials and components (including printed and non-printed components therefor).

 

“Maxitrol”
means the pharmaceutical product containing the active ingredients dexamethasone, neomycin sulfate and polymyxin B sulfate sold under
the brand name Maxitrol Suspension as marketed and sold by Novartis and/or its Affiliates under the relevant Product NDAs in the Territory
as of the date hereof. For the avoidance of doubt, for the purposes of this Agreement “Maxitrol” shall not include
pharmaceutical products marketed and sold by Novartis and/or its Affiliates under the brand name Maxitrol in any formulation (e.g. “ointment”)
other than as a suspension.

 

“Medical
Information” means information solely and exclusively relating to the Drug Substance or the Products in the Territory, existing,
owned, and used by Novartis or any of its Affiliates, and in Novartis’ possession as of the Closing Date, including clinical and
technical matters, such as therapeutic uses for the approved indications, drug-disease information, and other product characteristics.

 

“Moxeza”
means the pharmaceutical product containing the active ingredient moxifloxacin sold under the brand name Moxeza as marketed and sold
by Novartis and/or its Affiliates under the relevant Product NDAs in the Territory prior to the date hereof.

 

“NDA”
means (a) a New Drug Application, as defined in the Act, and (b) all supplements and amendments that may be filed with respect thereto.

 

“NDA
Data” means the existing readily available dossiers in Novartis’ possession as of the Closing Date containing the Know-How
actually used by Novartis and/or its Affiliates to obtain and maintain the Product NDAs in the Territory.

 

“NDA
Transfer Date” means the date upon which the FDA approves and notifies the Product NDA naming Purchaser or Purchaser’s
Affiliate or designate as the holder of the Product NDA.

 

“Novartis
Fundamental Representations” means the representations and warranties set forth in Section 7.1, Section 7.2,
Section 7.6 and Section 7.7(a) and (e).

 

“Other
Partners” means any Third Party to which Novartis and/or its Affiliates have sold any of the Products to outside the Territory
or Third Parties to which Novartis and/or its Affiliates may sell any of the Products to outside the Territory in the future.

 

“Patent
Assignment Agreement” means the Patent Assignment Agreement entered into between Purchaser and Novartis (or one or more of
its Affiliates) on the date hereof and effective as of the Closing Date.

 

“Patents”
means (a) pending patent applications, issued patents, utility models, and designs, (b) reissues, substitutions, confirmations, registrations,
validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or division of or
to any of the foregoing, (c) any other patent application claiming priority to any of the foregoing anywhere in the world, and (d) extension,
renewal, or restoration of any of the foregoing by existing or future extension, renewal, or restoration mechanics, including supplementary
protection certificates or the equivalent thereof.

 

    	6

     

    

 

“Permitted
Encumbrance” means (a) any Encumbrance for Taxes, assessments, and other governmental charges that are not yet due and payable,
(b) with respect to licenses, permits, or contracts, any restrictions, obligations, limitations, or other Encumbrances contained in such
license, permit, or contract or existing at Law or under the regulatory regime pursuant to which such license, permit, or contracts is
granted that do not materially impair the current use of the Drug Substance, the Products, the Transferred Assets, or the Licensed IP,
individually or in the aggregate, or (c) with respect to a NDA, in respect of the Products, any restrictions, obligations, limitations,
or other Encumbrances contained in such NDA or existing at Law or under the regulatory regime pursuant to which such NDA is granted that
do not materially impair the current use of the Drug Substance, the Products, the Transferred Assets, or the Licensed IP, individually
or in the aggregate.

 

“Person”
means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization, or
other entity.

 

“Pharmacovigilance
Agreement” means the Pharmacovigilance Agreement to be entered into by Purchaser and Novartis (or one or more of its Affiliates)
in accordance with Section 9.4.

 

“Phase
1 Period” has the meaning given to it in the Supply Agreement.

 

“Phase
2 Period” has the meaning given to it in the Supply Agreement.

 

“Products”
means each of Maxitrol, Iopidine and Moxeza (and “Product” shall mean either of them).

 

“Product
IP” means the Transferred IP or the Licensed IP, or both, as the context admits.

 

“Product
Liability Claim” means any suit, legal proceeding, arbitration proceeding, or any other claim for monetary or equitable relief
asserted by a Third Party arising out of the sale or use of the Drug Substance or the Products, including: (a) claims that arise from,
relate to or are in connection with injury or death to a human being claimed to have occurred as a result of the use of the Drug Substance
or the Products, whether premised on allegations of design or manufacturing defect, negligence, failure to provide an adequate warning,
breach of express or implied warranty, or any other legal theory, (b) claims that a Third Party was induced to purchase the Drug Substance
or the Products based on false or misleading representations or purchased or used the product for uses other than those indicated in
the product labelling as approved by the FDA or other Regulatory Authority, (c) claims that the sale of the Drug Substance or the Products
created a public nuisance, or (d) claims premised on regulatory action or voluntary action involving the Drug Substance or the Products,
such as recalls or withdrawal of the Products from the market.

 

“Product
NDAs” means the NDAs set forth on Annex 1.1(f).

 

“Purchased
Business” means Novartis’ business related to the Products.

 

    	7

     

    

 

“Purchaser
Fundamental Representations” means the representations and warranties set forth in Section 8.1, Section 8.2,
and Section 8.9.

 

“Records”
means the books, record, files, and other documentation of Novartis and/or its Affiliates as of the Closing Date, or pertinent portions
thereof, in each case to the extent solely and exclusively related to the Products in the Territory, to the extent owned, maintained,
and in the possession or control of Novartis or any of its Affiliates as of the Closing Date.

 

“Regulatory
Authority” means any Governmental Entity responsible for granting an NDA or an equivalent of an NDA in any jurisdiction outside
of the United States for the Products, including the FDA, any successor entity thereto, and any corresponding national or regional regulatory
authorities.

 

“Representatives”
means, with respect to any Person, the directors, officers, employees, managers, members, partners, equity holders, agents, consultants,
advisors (including legal counsel, accountants, and financial advisors), and representatives of such Person.

 

“Supply
Agreement” means the Supply Agreement entered into between Purchaser and Novartis (or one or more of its Affiliates) on the
date hereof and effective as of the Closing Date.

 

“Tax”
means all U.S. federal, state and local, and non-U.S. taxes and assessments, including all interest, penalties, and additions with respect
thereto.

 

“Territory”
means the United States.

 

“Third
Party” means any Person other than a Party or any Affiliate of a Party.

 

“Trademark
Assignment Agreement” means the trademark assignment agreement entered into between Purchaser and Novartis (or one or more
of its Affiliates) on the date hereof and effective as of the Closing Date.

 

“Transferred
Domain Names” means those domain names listed in Annex 1.1(a) under the heading “Transferred Domain Names”.

 

“Transferred
IP” means (a) the Transferred Patent, the Transferred Trademarks, and the Transferred Domain Names (and any and all intellectual
property rights in and to the foregoing), and (b) Commercial Information, Medical Information, Records, and NDA Data (and any and all
intellectual property rights in and to the foregoing), in each case in this clause (b), to the extent relating solely and exclusively
to the Products in the Territory, and in each case that are in existence as of the Closing Date, but not including any of the Licensed
IP.

 

“Transferred
Patent” means U.S. Patent No. 8450311.

 

“Transferred
Trademarks” means those registered trademarks and pending trademark applications in the Territory listed in Annex 1.1(e)
under the heading “Transferred Trademarks”, including all goodwill associated therewith.

 

    	8

     

    

 

“Transition
Services Agreement” means the Transition Services Agreement entered into between Purchaser and Novartis (or one or more of
its Affiliates) on the date hereof and effective as of the Closing Date.

 

“U.S.”
or “United States” means the United States of America, including all possessions and territories thereof.

 

1.2
Other Capitalized Terms. The following terms shall have the meanings specified in the indicated section of this Agreement:

 

	Term	 	Reference
	 	 	 
	Agreement	 	Preamble
	Assumed
    Liabilities	 	3.1
	Claim
    Notice	 	10.6(b)
	Closing	 	6.1
	Confidential
    Information	 	9.1
	Contracting
    Party	 	11.18
	Excluded
    Assets	 	2.1(b)
	Excluded
    Liabilities	 	3.2
	Indemnified
    Party	 	10.6(b)
	Indemnifying
    Party	 	10.6(b)
	Nonparty
    Affiliates	 	11.18
	Novartis
    Disclosure Schedule	 	7
	Novartis
    Indemnified Parties	 	10.3
	Novartis
    Names and Marks	 	9.3
	Parties	 	Preamble
	Party	 	Preamble
	Purchase
    Price	 	5.1(a)(i)
	Purchaser	 	Preamble
	Purchaser
    Disclosure Schedule	 	8
	Purchaser
    Indemnified Parties	 	10.2
	Qualifying
    Loss	 	10.4(c)
	Third-Party
    Claim	 	10.6(b)
	Transfer
    Taxes	 	5.2(a)
	Transferred
    Assets	 	2.1(a)
	Warranty
    Breach	 	10.4(c)

 

1.3
Interpretive Provisions. Unless the express context otherwise requires:

 

(a)
the words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement,
shall refer to this Agreement as a whole and not to any particular provision of this Agreement;

 

(b)
terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa;

 

(c)
the terms “Dollars” and “$” mean United States Dollars;

 

    	9

     

    

 

(d)
references herein to a specific Section, Article, Recital, Schedule, Annex, or Exhibit shall refer, respectively, to Sections, Articles,
Recitals, Schedules, Annexes, or Exhibits of this Agreement;

 

(e)
wherever the word “include,” “includes,” or “including” is used in this Agreement, it shall be deemed
to be followed by the words “without limitation”;

 

(f)
references herein to any gender shall include each other gender;

 

(g)
with respect to the determination of any period of time, the word “from” means “from and including” and the words
“to” and “until” each means “to but excluding”;

 

(h)
references herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented, or superseded,
in whole or in part, and in effect, as of the time at which such Law or license is referenced;

 

(i)
references herein to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder;

 

(j)
references to any agreement or contract are to that agreement or contract as amended, modified, or supplemented from time to time in
accordance with the terms thereof;

 

(k)
“extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase
does not mean simply “if”;

 

(l)
any documents or materials referred to herein as being “made available” to Purchaser shall have been provided to Purchaser
or its counsel at least one (1) Business Day prior to the date hereof; and

 

(m)
a Party includes its permitted assignees and/or the respective successors in title to substantially the whole of its undertaking.

 

ARTICLE
2

SALE
AND TRANSFER OF ASSETS

 

2.1
Purchase and Sale of Transferred Assets.

 

(a)
Transferred Assets. At the Closing, upon the terms and subject to the conditions set forth in this Agreement, including Section
2.1(b) and Section 2.2, Novartis shall, and shall cause its Affiliates to, sell, transfer, assign, convey, and deliver to
Purchaser, and Purchaser shall purchase and accept from Novartis, free and clear of any and all Encumbrances, except for Permitted Encumbrances,
if any, all of Novartis’ right, title, and interest in, to, and under the following assets, solely to the extent that they relate
exclusively to the Products in the Territory (the “Transferred Assets”):

 

(i)
the Product NDAs; and

 

(ii)
the Transferred IP.

 

    	10

     

    

 

(b)
Excluded Assets. Notwithstanding Section 2.1(a), nothing herein contained shall be deemed to sell, transfer, assign, convey,
or deliver to Purchaser, and Novartis (and its Affiliates, as applicable) shall retain all right, title, and interest in, to, and under
the following assets (the “Excluded Assets”):

 

(i)
the assets that relate to (A) any Ex-Territory Product, (B) any active product ingredient other than the Drug Substance, (C) any variant
of the Drug Substance, (D) any product other than the Products in the Territory, (E) any pharmaceutical products marketed and sold by
Novartis and/or its Affiliates under the brand name Maxitrol in any formulation other than as a suspension, or (F) any right to any NDA
or other right to sell products containing the Drug Substance held or used in the Territory by the Sandoz (generics) business of Novartis
AG;

 

(ii)
the Inventory (which shall be purchased by Purchaser in separate transactions subject to and in accordance with the terms and conditions
contained in the Supply Agreement);

 

(iii)
subject to the license rights granted to Purchaser in the License Agreement, the Licensed IP;

 

(iv)
the Novartis Names and Marks and any trademark, service mark, trade dress, logo, trade name, or corporate name similar or related thereto;

 

(v)
all accounts receivable, cash, and pre-paid expenses, whether or not relating to the Drug Substance, the Products or the Transferred
Assets for the period prior to the Closing Date (including payments received with respect thereto on or after the Closing Date);

 

(vi)
any real property and leaseholds (together with all fixtures and fittings related to any property), physical plant, machinery, equipment,
supplies, motor vehicles, and laboratory or office equipment;

 

(vii)
the global safety database relating to the Products and source documents associated with individual case safety reports;

 

(viii)
any rights or assets, including those with the same Drug Substances of the Products, belonging to the generic business of Sandoz (which
is the generic division of Novartis) or any of its successors, including for the avoidance of doubt any rights to (i) the dexamethasone
neomycin sulfate, polymyxin B sulfate product sold by Sandoz in the Territory under the ANDA A062341, or (ii) the 0.5% apraclonidine
hydrochloride sold by Sandoz in the Territory as an authorized generic product;

 

(ix)
any rights for countries outside the Territory;

 

(x)
any Excluded Agreements;

 

    	11

     

    

 

(xi)
any employees of Novartis and its Affiliates;

 

(xii)
any rights in the Territory relating to new combinations of the Drug Substance or the Products with one or more other active ingredient
or device;

 

(xiii)
any rights under Novartis’ insurance policies, whether or not related to the Drug Substance, the Products, or the Transferred Assets;

 

(xiv)
originals of books and records that Novartis and its Affiliates are required to retain pursuant to any Law, subject to Section 9.11;

 

(xv)
any books and records relating to employees of Novartis and/or its Affiliates;

 

(xvi)
any books and records that comprise Novartis’ or any of its Affiliates’ accounting or Tax records;

 

(xvii)
all refunds, claims for refunds, or rights to receive refunds from any Governmental Entity with respect to any and all Taxes paid or
to be paid by Novartis or any of its Affiliates (including any and all Taxes paid or to be paid by any of Novartis’ Affiliates
on behalf of Novartis);

 

(xviii)
all rights of Novartis arising under this Agreement or from the consummation of the transactions contemplated hereby; and

 

(xix)
all other assets, properties, rights, and interests of Novartis and its Affiliates not described in Section 2.1(a).

 

2.2
No Transfer of Certain Assets.

 

(a)
The Parties acknowledge and agree that, notwithstanding anything to the contrary in this Agreement, in no event shall this Agreement
be interpreted as a transfer of, nor shall it require the transfer, assignment, or assumption of, by either Party, any rights or obligations,
if the transferring party, or its Affiliates, do not have the right to transfer such rights and obligations or if such transfer, assignment,
or assumption would be in violation of applicable Law.

 

(b)
The Parties acknowledge and agree that, notwithstanding anything to the contrary in this Agreement, Novartis and its Affiliates will
not be obliged to sell, transfer, assign, convey, deliver, exercise or grant any licenses (under Section 4.1 or otherwise), or
perform any activities, and Purchaser will not be obliged to purchase, accept, exercise or grant any license rights (under Section
4.1 or otherwise) and will not perform any activities, related to any of the Transferred Assets and/or the Licensed IP to the extent
such Transferred Assets and/or the Licensed IP relate to countries that are, as of the date hereof, subject to comprehensive U.S. trade
sanctions (meaning country-wide sanctions not limited to specific sectors or parties) administered by the U.S. Treasury Department’s
Office of Foreign Assets Control.

 

    	12

     

    

 

2.3
Risk of Loss. Title and risk of loss or damage to the Transferred Assets shall pass to Purchaser on the Closing Date. As of the
Closing Date, the Transferred Assets shall cease to be insured by Novartis’ insurance policies or by Novartis’ self-insurance,
as the case may be, and Purchaser shall have no right or obligation with respect to any such policy.

 

ARTICLE
3

ASSUMED
LIABILITIES AND EXCLUDED LIABILITIES

 

3.1
Assignment and Assumption of Assumed Liabilities. At the Closing, upon the terms and subject to the conditions set forth in this
Agreement, Novartis shall assign to Purchaser, and, provided that Purchaser shall have no right to take any such action in Novartis’
(or any of its Affiliates’) name, Purchaser shall assume, be responsible for, and pay, perform, and discharge when due, any Liabilities
arising from the ownership or use of the Transferred Assets and/or the Licensed IP by or on behalf of Purchaser (or any of its successors
or assignees) or the manufacture, sale, marketing, distribution, or other commercialization of the Products by or on behalf of Purchaser
(or any of its successors or assignees), including (a) any Tax liabilities arising within the Territory after the Closing Date, and (b)
any Liabilities arising within or outside the Territory in respect of any Product Liability Claim, intellectual property infringement
claim or misappropriation claim brought by any Third Party after the Closing Date relating to the Drug Substance or the Products except,
in each case, to the extent arising out of Drug Substance or Products manufactured as of the Closing Date (collectively, “Assumed
Liabilities”).

 

3.2
Excluded Liabilities. Notwithstanding anything in this Agreement to the contrary, Purchaser shall not assume and shall not be
responsible to pay, perform or discharge and Novartis shall retain and remain responsible for and pay, perform, and discharge any and
all Liabilities other than the Assumed Liabilities (the “Excluded Liabilities”), including:

 

(a)
any Liabilities related to or arising out of the Excluded Assets;

 

(b)
any Liabilities under any of the Excluded Agreements;

 

(c)
any Liabilities in respect of any pending or threatened claim, demand, action or proceeding arising out of, relating to or otherwise
in respect of the Transferred Assets to the extent such claim, demand, action or proceeding relates to any period prior to the Closing
Date;

 

(d)
any Liabilities arising outside the Territory in respect of any Product Liability Claim, intellectual property infringement claim or
misappropriation claim brought by any Third Party in respect of Product that was sold outside the Territory by a party other than Purchaser
(or anyone acting on the behalf of Purchaser);

 

(e)
any Liabilities arising within the Territory in respect of any Product Liability Claim, intellectual property infringement claim or misappropriation
claim brought by any Third Party to the extent arising out of Drug Substance or Products manufactured as of the Closing Date;

 

    	13

     

    

 

(f)
any Liabilities associated with debt, loans or credit facilities of Novartis, any of its Affiliates owing to financial institutions;
and

 

(g)
any Liabilities arising out of, in respect of or in connection with the failure by Novartis or any of its Affiliates to comply with any
Law.

 

ARTICLE
4

GRANT
OF LICENSES

 

4.1
Grant of Licenses.

 

(a)
Licenses. The entire consideration for the licenses under the License Agreement shall form part of this Agreement (including the
Purchase Price and the transfer of Transferred Assets) and the licenses shall be fully paid-up, royalty-free, and perpetual.

 

(b)
Grant-back License. From and after the Closing, Purchaser hereby grants Novartis a non-exclusive, fully paid-up, royalty-free,
perpetual license, with the right to sublicense to its Affiliates or sub-contractors, under the Transferred IP and a right to use and
reference the NDAs in respect of the Drug Substance and the Products solely (i) to exercise Novartis’ rights and perform Novartis’
obligations under this Agreement, the Supply Agreement, and the other Ancillary Agreements, (ii) as necessary to comply with its obligations
under Law, (iii) to the extent it is reasonably necessary for the defense or prosecution of any legal or regulatory proceeding in which
Novartis or any of its Affiliates is a party or a potential party, (iv) to conduct research activities with respect to the Drug Substance
and/or Products in the Territory, and/or (v) to research, have researched, develop, have developed, use, have used, improve, have improved,
market, have marketed, practice, have practiced, make, have made, offer for sale, sell, have sold, distribute, have distributed, import,
have imported, export, have exported and otherwise exploit, have exploited, combinations of the Drug Substance or the Products with one
or more other active ingredient or device.

 

4.2
Reservation of Rights. From and after the Closing, without limiting any other rights that Novartis, its Affiliates, any of their
service providers, and/or Other Partners may have, Novartis, its Affiliates, any of their service providers, and/or Other Partners (a)
shall not be restricted from conducting research and development activities with respect to the Drug Substance, the Products, and/or
the Ex-Territory Products in the Territory, (b) may manufacture and import or have manufactured and imported the Ex-Territory Products
in the Territory solely for commercialization outside the Territory, and (c) may manufacture and import or have the Products manufactured
and imported within or outside the Territory for sale to Purchaser in accordance with the Supply Agreement. For the avoidance of doubt,
nothing in this Agreement or any Ancillary Agreement restricts Novartis and/or its Affiliates from developing, manufacturing, distributing,
and/or selling a combination product which includes both the Drug Substance as an active ingredient and another compound as an active
ingredient in the Territory.

 

4.3
Restriction to Territory.

 

(a)
From and after the Closing, Purchaser and its Affiliates may research, have researched, develop, have developed, manufacture, have manufactured,
use, have used, and import and/or have imported the Products outside the Territory for commercialization in the Territory. Purchaser
and its Affiliates shall not sell or promote the Products outside the Territory.

 

    	14

     

    

 

(b)
From and after the Closing, Novartis, its Affiliates, any of their service providers and/or Other Partners may manufacture and import
or have manufactured and imported the Ex-Territory Product in the Territory for commercialization outside the Territory. Except as contemplated
under the Supply Agreement, Novartis and its Affiliates shall not sell or promote or otherwise commercialize the Products or the Ex-Territory
Product in the Territory.

 

(c)
If Purchaser or its Affiliates enter into an agreement to have the Products sold or promoted by a Third Party, the rights to have the
Products sold or promoted shall be limited to jurisdictions within the Territory. If Purchaser or its Affiliates sells, transfers, or
otherwise divests to a Third Party the Product NDAs and rights to sell, promote, have sold, or have promoted the Products, then the rights
to have the Products sold or promoted shall be limited (to the extent permitted by applicable Law) to jurisdictions within the Territory.

 

(d)
If Novartis or its Affiliates enter into an agreement to have an Ex-Territory Product sold or promoted by a Third Party, the rights to
have such Ex-Territory Product sold or promoted shall be limited to jurisdictions outside the Territory. If Novartis or its Affiliates
sells, transfers, or otherwise divests to an Other Partner the Products marketing authorizations (including any equivalent of an NDA
in any jurisdiction outside of the United States) and rights to sell, promote, have sold, or have promoted an Ex-Territory Product, then
the rights to have such Ex-Territory Product sold or promoted shall be limited (to the extent permitted by applicable Law) to jurisdictions
outside the Territory.

 

ARTICLE
5

PAYMENTS

 

5.1
Consideration.

 

(a)
The total consideration for the purchase of the Transferred Assets as described herein and for the provision of the licenses under the
License Agreement shall be:

 

(i)
an amount in cash equal to USD $14,050,000 (fourteen million fifty thousand US dollars) (the “Purchase Price”); and

 

(ii)
the assumption of the Assumed Liabilities.

 

(b)
Purchaser acknowledges and agrees that the total consideration set forth in Section 5.1(a) shall not be reduced and no part of
such consideration shall be refunded, and Novartis and its Affiliates shall have no liability of any kind to Purchaser or its Affiliates
in the event that any NDA in respect of the Drug Substance or the Products is not transferred to Purchaser for any reason. All payments
shall be made free and clear of, and without deduction for, withholdings, Taxes or other charges of any kind and of any country.

 

(c)
The Parties agree that, for all purposes, the Purchase Price shall be allocated to the individual Products as set out in Annex 5.1(c).

 

    	15

     

    

 

5.2
Taxes.

 

(a)
Purchaser shall bear any transfer Tax imposed in the Territory in connection with the transactions contemplated in this Agreement (“Transfer
Taxes”) and shall make any corresponding tax declarations in the Territory that may be required.

 

(b)
Each Party shall be responsible for any Tax obligations of its own due to this Agreement (including income Tax and capital gains Tax).
Neither Party shall have any obligation towards the other Party in case that the other Party fails to fully comply with its Tax obligations.

 

(c)
For all Tax purposes, both Parties agree to report the transactions contemplated by this Agreement in a manner consistent with its terms
and to not take any position inconsistent therewith in any Tax return, refund claim, litigation, or otherwise.

 

ARTICLE
6

THE
CLOSING

 

6.1
Closing. Subject to the satisfaction or waiver of all the conditions set forth in ARTICLE 10, the closing of the transactions
contemplated by this Agreement (the “Closing”) shall take place at the offices of NPC or such other place as the parties
may agree (or, if agreed by the parties, remotely by electronic means) on the date hereof or on such earlier date as mutually agreed
by the Parties. The Closing shall be deemed to have occurred as of 12:01 a.m. New York City time, on the Closing Date, such that Purchaser
shall be deemed the owner of the Transferred Assets on and after the Closing Date.

 

6.2
Deliverables.

 

(a)
The Parties acknowledge and agree that simultaneously with the execution of this Agreement, Novartis and Purchaser shall have executed
and delivered to each other duly executed copies of the following agreements, which shall become effective as of Closing in accordance
with their terms:

 

(i)
the Alcon Sublicense Agreement;

 

(ii)
the Commercial Agreement;

 

(iii)
the Domain Name Assignment Agreement;

 

(iv)
the License Agreement;

 

(v)
the Supply Agreement;

 

(vi)
the Patent Assignment Agreement;

 

(vii)
the Trademark Assignment Agreement; and

 

(viii)
the Transition Services Agreement.

 

    	16

     

    

 

(b)
At the Closing, the Parties shall execute and deliver other documents and instruments of sale, assignment, transfer, and conveyance as
are reasonably necessary to effectuate the transactions contemplated by this Agreement to occur on the Closing Date, including the Bill
of Sale & Assignment and Assumption Agreement.

 

(c)
At the Closing, Purchaser shall (i) pay the Purchase Price to Novartis, free and clear of, and without deduction for, withholdings, Taxes,
or other charges of any kind and of any country, by wire transfer into the bank account specified below, and (ii) deliver to Novartis
a U.S. Federal Reserve reference or similar number evidencing execution of such payment. For the avoidance of doubt, the Parties acknowledge
and agree that the Closing shall not occur until Novartis shall have confirmed receipt of the entirety of the Purchase Price at following
bank account:

 

Name
of Company: NOVARTIS TECHNOLOGY LLC

Company
Address: 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 US

Citibank
Branch: Citibank N.A. New York

Swift
Code: CITIUS33

ABA:
021000089

Account
No.: 31178485

 

ARTICLE
7

REPRESENTATIONS
AND WARRANTIES OF NOVARTIS

 

Novartis
represents and warrants to Purchaser, subject to the exceptions disclosed in the disclosure schedules provided by Novartis to Purchaser
concurrently with the execution of this Agreement (the “Novartis Disclosure Schedule”), as follows:

 

7.1
Organization; Qualification. Novartis is a company duly organized, validly existing, and in good standing under the laws of the
jurisdiction of its formation. Novartis is duly qualified to do business and in good standing (to the extent such concept is recognized
by the applicable jurisdiction) as a foreign entity in each jurisdiction in which the nature of its business or the ownership, lease,
or operation of its assets and properties makes such qualification necessary, except where the failure to be so qualified or to be in
good standing would not reasonably be expected to have a Material Adverse Effect.

 

7.2
Authority; Enforceability. Novartis has the requisite organizational power and authority to enter into this Agreement and the
Ancillary Agreements and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement
and, as of the Closing, each of the Ancillary Agreements, by Novartis and the consummation of the transactions contemplated hereby and
thereby have been duly and validly authorized and no other organizational proceedings on the part of Novartis are required therefor.
This Agreement has been, and the Ancillary Agreements, as of the Closing, will be, duly executed and delivered by Novartis and, assuming
the due authorization, execution, and delivery of this Agreement and, as of the Closing, each of the Ancillary Agreements, by Purchaser,
will constitute the legal, valid, and binding obligation of Novartis, enforceable against Novartis in accordance with their terms, subject
to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer, or other similar Laws affecting or relating to the enforcement
of creditors’ rights generally from time to time in effect, and to general principles of equity.

 

    	17

     

    

 

7.3
No Violations; Consents. Except for the Authorizations listed in Section 7.3 of the Novartis Disclosure Schedule, the execution
and delivery of this Agreement does not and, as of the Closing, the execution and delivery of the Ancillary Agreements will not, and
the consummation of the transactions contemplated hereby and thereby and the compliance with the terms hereof and thereof will not (i)
violate any Law applicable to Novartis, the Drug Substance, the Products, the Transferred Assets, or the Licensed IP, (ii) conflict with
any provision of the charter or by-laws (or similar organizational documents) of Novartis, or (iii) require any approval, authorization,
consent, license, exemption, filing, or registration with any court, arbitrator, or Governmental Entity.

 

7.4
Litigation. Except as disclosed in Section 7.4 of the Novartis Disclosure Schedule, there is no suit, claim, action, investigation,
or proceeding pending or, to the Knowledge of Novartis, threatened against Novartis or any of its Affiliates, that relates to the Drug
Substance, the Products, the Transferred Assets, or the Licensed IP. There are no outstanding orders, injunctions, or decrees of any
Governmental Entity that apply to any of the Transferred Assets that restrict the ownership, disposition, or use of any of the Transferred
Assets.

 

7.5
Debarred Personnel. Neither Novartis nor any of its Affiliates nor any of Novartis’ or its Affiliates’ employees or
consultants has been debarred or deemed subject to debarment pursuant to Section 306 of the Act nor, to the Knowledge of Novartis, are
any such Persons the subject of a conviction described in such section.

 

7.6
Title to Assets. Novartis has good, valid and marketable title to, or a valid and enforceable license or other right to use (as
applicable), all of the Transferred Assets. All of the Transferred Assets owned or purported to be owned by Novartis are owned free and
clear of all Encumbrances other than Permitted Encumbrances.

 

7.7
Intellectual Property.

 

(a) To the Knowledge of Novartis, the Product IP constitutes all of the material intellectual property
rights owned by or licensed to Novartis or its Affiliates which is used by Novartis and/or its Affiliates to manufacture, sell, market,
distribute, or otherwise commercialize the Products as of the date hereof. Neither Novartis nor any of its Affiliates owns, licenses
or otherwise controls any Patents that are reasonably necessary to manufacture, sell, market, distribute, or otherwise commercialize
the Products

 

(b)
Annex 1.1(a) and, Annex 1.1(e), contain true and complete lists of all trademarks, and domain names included in the Product
IP. Neither Novartis nor any of its Affiliates is a party to any license or similar agreement under which it has granted a license or
other rights to any Third Party in respect of the Drug Substance or the Products which would conflict in any material respect with the
rights being conveyed or licensed to Purchaser under this Agreement or the License Agreement, respectively.

 

    	18

     

    

 

(c)
To the Knowledge of Novartis, the manufacture, sale,
offer for sale, or importation of the Products in the Territory, as it is manufactured, sold, offered for sale, or imported as of the
date hereof, does not infringe, misappropriate, or otherwise violate in any material respect the intellectual property rights of any
Third Party in the Territory. To the Knowledge of Novartis, none of the Product IP has been adjudged invalid or unenforceable in whole
or part and all such Product IP is valid and enforceable, other than abandoned Patents and the opinions of the U.S. Patent and Trademark
Office with respect to currently pending patent applications and trademark applications or registered trademarks which are vulnerable
for non-use cancellation. As of the date hereof, there is, in the Territory, no suit, claim, action, investigation, or proceeding pending
or, to the Knowledge of Novartis, threatened in writing against Novartis or any of its Affiliates, that relates to the Product IP (i)
based upon, or challenging or seeking to deny or restrict, the rights of Novartis or any of its Affiliates in any of the Product IP,
or (ii) alleging that the Products, or any processes used to manufacture the Products, conflict with, misappropriate, infringe, or otherwise
violate any intellectual property rights of any Third Party in the Territory.

 

(d)
To the Knowledge of Novartis, no Third Party is infringing
any of the Product IP.

 

(e)
Novartis is the sole and exclusive legal and beneficial
owner of all right, title and interest in and to the Transferred IP, and has the valid and enforceable right to use all Licensed IP,
free and clear of Encumbrances other than Permitted Encumbrances.

 

(f)
Neither the execution, delivery, or performance of this
Agreement, nor the consummation of the transactions contemplated hereby, will result in the loss or impairment of or payment of any additional
amounts with respect to, or require the consent of any other Person in respect of, Purchaser’s right to own or use any Product
IP. Immediately, following the Closing, all Transferred IP and Licensed IP will be owned or available, respectively, for use by Purchaser
on identical terms as they were owned or available for use by Novartis immediately prior to the Closing.

 

(g)
Novartis has taken commercially reasonable steps to
maintain and enforce the Product IP and to preserve the confidentiality of all trade secrets included in the Product IP.

 

7.8
Compliance with Applicable Law. Neither Novartis
nor any of its Affiliates is in violation of any applicable Law, which could reasonably be expected to prevent or materially delay the
consummation of the transactions contemplated hereby or materially interfere with Novartis’ performance of its obligations hereunder.

 

    	19

     

    

 

7.9
Exclusivity of Representations. Except for the
representations and warranties contained in this ARTICLE 7 (as modified by the Novartis Disclosure Schedule) and in the Ancillary
Agreements, neither Novartis nor any other Person makes any other express or implied representation or warranty with respect to the Drug
Substance, the Products, the Transferred Assets, the Assumed Liabilities, or the Licensed IP, or the transactions contemplated by this
Agreement, and Novartis disclaims any other representations or warranties, whether made by Novartis, its Affiliates, or any of their
respective Representatives. Except for the representations and warranties contained in this ARTICLE 7 (as modified by the Novartis
Disclosure Schedule) and in the Ancillary Agreements, Novartis hereby disclaims all liability and responsibility for any representation,
warranty, projection, forecast, statement, or information made, communicated, or furnished (whether orally or in writing, in any “data
room” relating to the transactions contemplated by this Agreement, in management presentations, functional “break-out”
discussions, responses to questions or requests submitted by or on behalf of Purchaser, or in any other form in consideration or investigation
of the transactions contemplated by this Agreement) to Purchaser, its Affiliates, or any of their respective Representatives (including
any opinion, information, forecast, projection, or advice that may have been or may be provided to Purchaser, its Affiliates, or any
of their respective Representatives by any Representative of Novartis or any of its Affiliates). Novartis makes no representations or
warranties to Purchaser, its Affiliates, or any of their respective Representatives regarding (a) merchantability or fitness for any
particular purpose, or (b) the probable success or profitability of the Drug Substance, the Products, the Transferred Assets, the Assumed
Liabilities, or the Licensed IP. Without limiting the generality of the foregoing, Purchaser acknowledges and agrees that, except as
expressly provided in this Agreement or in the Ancillary Agreements, Purchaser is acquiring the Transferred Assets on an “as is,
where is” basis. 

 

ARTICLE
8 

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Purchaser
represents and warrants to Novartis, subject to the exceptions disclosed in the disclosure schedules provided by Purchaser to Novartis
concurrently with the execution of this Agreement (the “Purchaser Disclosure Schedule”), as follows:

 

8.1
Organization; Qualification. Purchaser is a corporation
duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation. Purchaser is duly qualified
to do business and in good standing (to the extent such concept is recognized by the applicable jurisdiction) as a foreign entity in
each jurisdiction in which the nature of its business or the ownership, lease, or operation of its assets and properties makes such qualification
necessary, except where the failure to be so qualified or be in good standing would not reasonably be expected to prevent or materially
delay the consummation of the transactions contemplated hereby. Purchaser is a pharmaceutical company, which, together with its Affiliates
and distributors, has the necessary technical and commercial resources and expertise to assume from Novartis the Transferred Assets and
related obligations under the terms, conditions, and timelines contained in this Agreement and the Ancillary Agreements.

 

8.2
Authority; Enforceability. Purchaser has the
requisite organizational power and authority to enter into this Agreement and the Ancillary Agreements and to consummate the transactions
contemplated hereby and thereby. The execution and delivery of this Agreement and, as of the Closing, each of the Ancillary Agreements,
by Purchaser and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized and no other
organizational proceedings on the part of Purchaser are required therefor. This Agreement has been, and the Ancillary Agreements, as
of the Closing, will be, duly executed and delivered by Purchaser and, assuming the due authorization, execution, and delivery of this
Agreement and, as of the Closing, the Ancillary Agreements, by Novartis, will constitute the legal, valid, and binding obligations of
Purchaser, enforceable against Purchaser in accordance with their terms, subject to bankruptcy, insolvency, reorganization, moratorium,
fraudulent transfer, or other similar Laws affecting or relating to the enforcement of creditors’ rights generally from time to
time in effect, and to general principles of equity.

 

    	20

     

    

 

8.3
No Violations; Consents. Except for (a) any filings
with Governmental Entities or other Authorizations necessary to transfer the Transferred Assets, and (b) the Authorizations listed in
Section 8.3 of the Purchaser Disclosure Schedule, the execution and delivery of this Agreement do not, and, as of the Closing,
the execution and delivery of the Ancillary Agreements will not, and the consummation of the transactions contemplated hereby and thereby
and the compliance with the terms hereof and thereof will not (i) violate any Law applicable to Purchaser, (ii) conflict with any provision
of the certificate of incorporation or by-laws (or similar organizational documents) of Purchaser, or (iii) require any approval, authorization,
consent, license, exemption, filing, or registration with any court, arbitrator, or Governmental Entity, except with respect to the foregoing
clause (iii), for such approvals, authorizations, consents, licenses, exemptions, filings, or registrations which have been obtained
or made or which, if not obtained or made, would not reasonably be expected to prevent or materially delay the consummation of the transactions
contemplated hereby or materially interfere with Purchaser’s performance of its obligations hereunder.

 

8.4
Litigation. Except as disclosed in Section
8.4 of the Purchaser Disclosure Schedule, there is no suit, claim, action, investigation, or proceeding pending or, to the Knowledge
of Purchaser, threatened in writing against Purchaser or any of its Affiliates, which (a) would reasonably be expected to prevent or
materially delay the consummation of the transactions contemplated hereby or materially interfere with Purchaser’s performance
of its obligations hereunder, or (b) challenges or seeks to prevent or enjoin the transactions contemplated by this Agreement or any
of the Ancillary Agreements. There are no outstanding orders, injunctions, or decrees of any Governmental Entity that apply to Purchaser
that restrict the ownership, disposition, or use of any of the Transferred Assets in a manner that would reasonably be expected to prevent
or materially delay the consummation of the transactions contemplated hereby or materially interfere with Purchaser’s performance
of its obligations hereunder.

 

8.5
Debarred Personnel. Neither Purchaser nor any
of its Affiliates nor any of Purchaser’s or its Affiliates’ employees or consultants has been debarred or deemed subject
to debarment pursuant to Section 306 of the Act nor, to the Knowledge of Purchaser, are any such Persons the subject of a conviction
described in such section. 

 

8.6
Availability of Funds. 

 

(a)
At the Closing, Purchaser will have immediately available
cash that is sufficient to pay the full consideration payable hereunder, to satisfy all of the Assumed Liabilities, and to make all other
necessary payments in connection with the transactions contemplated by, and to perform its obligations under, this Agreement and the
Ancillary Agreements.

 

    	21

     

    

 

(b)
After giving effect to the transactions contemplated
hereby, including the payment of all amounts set forth in Section 8.6(a) (including all related fees and expenses), Purchaser
will not (i) be insolvent (because (x) Purchaser’s financial condition is such that the sum of its debts is greater than the fair
value of its assets, (y) the present fair saleable value of Purchaser’s assets will be less than the amount required to pay Purchaser’s
probable liability on its debts as they become absolute and matured, or (z) Purchaser is unable to pay all of its debts as and when they
become due and payable), (ii) have unreasonably small capital with which to engage in its business, or (iii) have incurred or plan to
incur debts beyond its ability to pay as they become absolute and matured.

 

8.7
Compliance with Applicable Law. 

 

(a)
To the Knowledge of Purchaser, neither Purchaser nor
any of its Affiliates is in violation of any applicable Law, which would reasonably be expected to prevent or materially delay the consummation
of the transactions contemplated hereby or materially interfere with Purchaser’s performance of its obligations hereunder.

 

(b)
Purchaser is aware of the applicable Law relating to
marketing, distribution, and sale of the Products in the Territory, and will be able to legally import, export, store, market, distribute,
and sell the Products in the Territory immediately as of the Closing.

 

(c)
As of the NDA Transfer Date, Purchaser or its Affiliates
shall have the full organizational and regulatory authority to own, hold, and use the Product NDAs.

 

8.8
No Knowledge of Misrepresentation or Omission.
As of the date of this Agreement, none of the individuals listed on Annex 1.1(c) have actual knowledge (without having conducted or having
any duty to conduct any investigation) that the representations and warranties of Novartis made in this Agreement are inaccurate or untrue
(including as qualified by the Novartis Disclosure Schedules).

 

8.9
Independent Assessment; No Inducement or Reliance.
Purchaser agrees and acknowledges that, except for the representations and warranties expressly set forth in ARTICLE 7 (as modified
by the Novartis Disclosure Schedule), neither Novartis nor any of its Affiliates, or any of their respective Representatives, or any
other Person has made or is making, and Purchaser has not relied upon and is not relying upon, any other representations or warranties,
promises, covenants, agreements, or guaranties, statutory, common law, or otherwise, of any nature, oral or written, past, present, or
future, including any other representations or warranties, express or implied. In addition, Purchaser has not relied upon and is not
relying upon the accuracy or completeness of any other information, made by, or made available by, Novartis, its Affiliates or any of
their respective Representatives, with respect to, or in connection with, the negotiation, execution, or delivery of this Agreement or
the transactions contemplated hereby, notwithstanding the delivery or disclosure of any documentation or other information with respect
to any one or more of the foregoing, including in any “data room” relating to the transactions contemplated by this Agreement,
in management presentations, functional “break-out” discussions, responses to questions or requests submitted by or on behalf
of Purchaser, or in any other form provided or made available to Purchaser or its Representatives in anticipation or contemplation of
any of the transactions contemplated hereby. Furthermore, in connection with the due diligence investigation of the Drug Substance, the
Products, the Transferred Assets, the Assumed Liabilities, and the Licensed IP by and on behalf of Purchaser, Purchaser and its Representatives
have received and may continue to receive from Novartis, its Affiliates, or any of their respective Representatives certain estimates,
projections, forecasts, and other forward-looking information, as well as certain business plan information, regarding the Drug Substance,
the Products, the Transferred Assets, the Assumed Liabilities, and the Licensed IP. Purchaser hereby acknowledges that there are uncertainties
inherent in attempting to make such estimates, projections, forecasts, and other forward-looking statements, as well as in such business
plans, with which Purchaser is familiar, that Purchaser is taking full responsibility for making its own evaluation of the adequacy and
accuracy of all estimates, projections, forecasts, and other forward-looking information, as well as such business plans, so furnished
to it (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking information,
or business plans), and that Purchaser will have no claim against Novartis, its Affiliates, or any of their respective Representatives,
with respect thereto. Accordingly, Purchaser hereby acknowledges that none of Novartis, its Affiliates, or any of their respective Representatives,
has made or is making any representation or warranty with respect to, and Purchaser has not relied upon, such estimates, projections,
forecasts, forward-looking statements, or business plans (including the reasonableness of the assumptions underlying such estimates,
projections, forecasts, forward-looking statements, or business plans).

 

    	22

     

    

 

8.10
Exclusivity of Representations. Except for the
representations and warranties contained in this ARTICLE 8 (as modified by the Purchaser Disclosure Schedule) and in the Ancillary Agreements,
neither Purchaser nor any other Person makes any other express or implied representation or warranty with respect to the transactions
contemplated by this Agreement, and Purchaser disclaims any other representations or warranties, whether made by Purchaser, its Affiliates,
or any of their respective Representatives.

 

ARTICLE
9 

COVENANTS

 

The
Parties covenant and agree as follows:

 

9.1
Confidentiality. Each of Novartis and Purchaser
covenants and agrees that neither it nor any of its Affiliates shall disclose any Confidential Information (as defined below) to any
Third Party other than to (a) its and its Affiliates’ respective Representatives who need to know such information and who are
bound by restrictions regarding disclosure and use of such Confidential Information comparable to and no less restrictive than those
set forth herein, and (b) actual and proposed (sub)licensees, manufacturers, suppliers, contractors, distributors, and permitted assignees
who are bound in writing by restrictions regarding disclosure and use of the Confidential Information comparable to and no less restrictive
than those set forth herein; provided that Purchaser may disclose Confidential Information in confidence to any Person with whom
such Purchaser has, or is proposing to enter into, a business relationship related to any of the Transferred Assets and to any Governmental
Entity for purposes of obtaining approval to test or market a Product. For purposes of this Section 9.1, “Confidential
Information” means (1) any confidential or proprietary information of, or concerning, the Drug Substance, the Products, the
Transferred Assets, or the Licensed IP, and (2) the terms and conditions of this Agreement and the Ancillary Agreements and the transactions
contemplated hereby and thereby. The obligations of confidentiality set forth in this Agreement shall not apply to any such Confidential
Information that: (i) is independently developed without access to or use of the Confidential Information; (ii) is or becomes (or has
already become) publicly available without breach of this Agreement or any Ancillary Agreement; or (iii) is rightfully received from
a Third Party without obligation of confidentiality having the right to disclose such Confidential Information. In addition, notwithstanding
the confidentiality obligations set forth in this Agreement, each Party may disclose Confidential Information to the extent the disclosure
of which is consented to by the other Party in writing or the disclosure of which is requested or required by a Governmental Entity or
applicable Law, rule (including rule of a stock exchange, listing agency or automated quotation system) or legal process (whether by
statute, rule, regulation, court order, requests for information in legal proceedings, subpoena, civil investigative demand, or other
similar process). In maintaining the confidentiality of Confidential Information, each Party shall exercise the same degree of care that
it exercises with its own confidential information, and in no event less than a reasonable degree of care. Effective as of the Closing,
this Section 9.1 shall supersede the Confidentiality Agreement in all respects and all confidential information shared pursuant
to the Confidentiality Agreement prior to the Closing shall be deemed Confidential Information for purposes hereof.

 

9.2
Press Releases. Neither Party shall issue any
press release, trade announcement, or make any other public announcement with regard to the transactions contemplated by this Agreement
without the other Party’s prior written consent, which shall not be unreasonably withheld, conditioned, or delayed. This restriction
shall not apply to announcements required by any Laws applicable to the Parties or any of their respective Affiliates, by a request by
a Governmental Entity, or by an obligation pursuant to the rules of any securities exchange (and only to the extent so required); provided,
however, that in such event the Parties shall, to the extent reasonably practicable, reasonably cooperate to agree upon the content
and wording of any such announcements. Each Party acknowledges that the other Party shall have the right to (a) disclose a brief summary
of the transactions contemplated by this Agreement, including the Purchase Price, in its official financial reports, and (b) communicate
with its customers, suppliers, distributors, and other contractual counterparties, regarding this Agreement, the Ancillary Agreements,
and the transactions contemplated hereby or thereby, including in order to obtain consents of or from any such Person necessary or desirable
to effect the consummation of the transactions contemplated hereby or thereby. To the extent any Party is required to file a copy of
this Agreement or any Ancillary Agreement as an exhibit to any filings with, or otherwise publicly disclose the terms hereof or thereof
to, any securities exchange or any other Governmental Entity, the Parties shall use reasonable efforts to coordinate in advance on the
form of redacted version of this Agreement or applicable Ancillary Agreement or the terms to be so filed or disclosed and permit the
other Party to provide comments and take such comments into account in good faith prior to making such filing.

 

9.3
Novartis Names and Marks. Purchaser hereby acknowledges
that all right, title, and interest in and to the names “Novartis,” “Ciba-Geigy,” or “Sandoz” and
the “Novartis,” “Ciba-Geigy,” or “Sandoz” logos, together with all variations thereof and all trademarks,
service marks, domain names, trade names, trade dress, corporate names, and other identifiers of source containing, incorporating or
associated with any of the foregoing (the “Novartis Names and Marks”) are owned exclusively by Novartis and/or its
Affiliates. Purchaser further acknowledges that it has no rights, and is not acquiring any rights, to use the Novartis Names and Marks,
except as expressly provided in the Supply Agreement.

 

    	23

     

    

 

9.4
Pharmacovigilance Agreement; Other Obligations.

 

(a)
Negotiation of Pharmacovigilance Agreement. Following
the Closing, the Parties shall negotiate in good faith and use their respective reasonable best efforts to negotiate and finalize the
Pharmacovigilance Agreement as promptly as practicable, and in any event, before it is required by any jurisdiction in the Territory.
Between the Closing Date and the execution of the Pharmacovigilance Agreement, each Party shall (i) notify the other Party in writing
within two (2) calendar days of becoming aware of any Adverse Events, complaints, or other safety-related issues with respect to the
Products (or Ex-Territory Products, as applicable), and (ii) cooperate with the other Party in investigating any such Adverse Events,
complaints, or other safety-related issues.

 

(b)
Medical and Other Inquiries. Except to the extent
otherwise provided in this Agreement or any Ancillary Agreement, from and after the applicable NDA Transfer Date, Purchaser (i) shall
be responsible for handling and responding to all customer complaints and inquiries (including medical and non-medical inquiries) related
to the Products, and (ii) shall be responsible for all correspondence and communication with physicians and other health care professionals
relating to the Products.

 

9.5
Transferring of Product NDAs. The Parties shall
provide written notice to the FDA before the end of the Phase 1 Period, of the transfer of the Product NDAs from Novartis to the Purchaser.
Purchaser shall bear (either directly when feasible or by way of reimbursement to Novartis) the Third-Party fees levied by FDA or any
other Governmental Entities in the Territory and any other relevant costs for such transfer to Purchaser.

 

9.6
Maintenance of Product NDAs Pending Notification
of Transfer to the FDA.

 

Until
notification of transfer of the Product NDAs to the FDA pursuant to Section 9.5:

 

(a)
Novartis shall use its commercially reasonable efforts
to maintain the Product NDAs;

 

(b)
Novartis shall
be free to continue to pursue those ongoing variations, amendments, and renewals of the Product NDAs which are pending at the Closing
Date or withdraw them, at its own discretion; and

 

(c)
Novartis shall
not initiate any additional variations or amendments of the Product NDAs, except in the event they are indispensable for the manufacture,
sale, marketing, distribution, or other commercialization of the Product and upon Purchaser’s
written request.

 

9.7
Recordations and Filings. Following the Closing
Date, Purchaser shall be responsible for and bear, and reimburse Novartis for, any and all costs associated with any recordation of the
Patent Assignment Agreement, the Trademark Assignment Agreement, and the Domain Name Assignment Agreement

 

    	24

     

    

 

9.8
Authorized generic agreement. Following the Closing
Date, Purchaser shall negotiate in good faith with Sandoz to agree an authorized generics agreement which shall entitle Sandoz to continue
to commercialize the 0.5% apraclonidine hydrochloride product sold by it in the Territory as an authorized generic product as at the
date of this Agreement. For the avoidance of doubt, from the Closing Date until an authorized generics agreement is signed between Sandoz
and Purchaser, Sandoz shall remain entitled to continue to commercialize the 0.5% apraclonidine hydrochloride product sold by it in the
Territory.

 

9.9
Accounts Receivable and Payable.

 

(a)
Accounts Receivable. The Parties acknowledge
and agree that all accounts receivable outstanding on the Closing Date shall remain the property of Novartis or its Affiliates and shall
be collected by Novartis or its Affiliates subsequent to the Closing. In the event that, subsequent to the Closing, Purchaser or an Affiliate
of Purchaser receives any payments from any obligor with respect to an account receivable or other payment belonging to Novartis, then
Purchaser shall, within thirty (30) calendar days after receipt of such payment, remit the full amount of such payment to Novartis. In
the case of the receipt by Purchaser of any payment from any obligor of both Novartis and Purchaser then, unless otherwise specified
by such obligor, such payment shall be applied first to amounts owed to Purchaser with the excess, if any, remitted to Novartis. In the
event that, subsequent to the Closing, Novartis or any of its Affiliates receives any payments from any obligor with respect to an account
receivable of Purchaser for any period after the Closing Date or other payment belonging to Purchaser, then Novartis shall, within thirty
(30) calendar days after receipt of such payment, remit the full amount of such payment to Purchaser. In the case of the receipt by Novartis
of any payment from any obligor of both Novartis and Purchaser then, unless otherwise specified by such obligor, such payment shall be
applied first to amounts owed to Novartis with the excess, if any, remitted to Purchaser.

 

(b)
Accounts Payable. In the event that, subsequent
to the Closing, Purchaser or an Affiliate of Purchaser receives any invoices from any Third Party with respect to any account payable
of the Transferred Assets outstanding prior to the Closing, then Purchaser shall, within thirty (30) days after receipt of such invoice,
provide such invoice to Novartis. In the event that, subsequent to the Closing, Novartis or any of its Affiliates receives any invoices
from any Third Party with respect to any account payable of Purchaser or any of its Affiliates for any period after the Closing, then
Novartis shall, within thirty (30) calendar days after receipt of such invoice, provide such invoice to Purchaser.

 

9.10
Wrong Pockets. For a period of up to twelve (12)
months after the Closing Date, if either Purchaser or Novartis becomes aware that any of the Transferred Assets have not been transferred
to Purchaser or that any of the Excluded Assets have been transferred to Purchaser, it shall promptly notify the other Party in writing
and the Parties shall, as soon as reasonably practicable, ensure that such property is transferred, and with any necessary prior Third
Party consent or approval, to (a) Purchaser, in the case of any Transferred Asset which was not transferred to Purchaser at the Closing;
or (b) Novartis, in the case of any Excluded Asset which was transferred to Purchaser at the Closing.

 

    	25

     

    

 

9.11
Transfer of Books and Records. Novartis and its
Affiliates, as applicable, (a) shall provide copies (redacted to the extent necessary to remove any confidential information not related
to the Drug Substance of the Products) of books and records that Novartis and its Affiliates are required to retain pursuant to any Law
to the extent relating to the Drug Substance of the Products upon Purchaser’s reasonable request, and (b) may destroy such books
and records in accordance with their prevailing records retention procedures to the extent such books and records are no longer required
to maintain by Law so long as Novartis and its Affiliates have previously provided copies of such books and records pursuant to clause
(a) of this Section 9.11. 

 

9.12
Preservation of Records; Novartis’ Access.
For a period of six (6) years after the Closing Date, (a) Purchaser agrees to retain (and to cause its Affiliates to retain) and make
available all Records included in the Transferred Assets received from Novartis and its Affiliates for inspection and copying by Novartis,
its Affiliates, or any of their respective Representatives, at Novartis’ expense, upon reasonable request and upon reasonable notice;
provided that such Records shall be made available only to the extent such availability is required for Novartis or an Affiliate
for Tax and accounting purposes, to comply with any requirement of Law, legal, judicial, or administrative process, this Agreement or
the Ancillary Agreements, or to enable Novartis or an Affiliate to defend against, respond to, or otherwise participate in any litigation,
investigation, audit process, subpoena, or other proceeding related to the Drug Substance and/or the Products, and (b) no such Records
shall be destroyed by Purchaser without first advising Novartis in writing and giving Novartis a reasonable opportunity, at Novartis’
sole cost, to obtain possession thereof. Any such access by Novartis shall not unreasonably interfere with the conduct of the business
of Purchaser and its Affiliates. Novartis shall hold, and shall cause its Representatives to hold, in confidence, unless required by
legal, judicial, or administrative process or by other requirements of applicable Law, all confidential documents and information concerning
Purchaser or the Drug Substance, Products, Transferred Assets, and Assumed Liabilities provided to it pursuant to this Section 9.12.
The Parties acknowledge and agree that Novartis may retain a copy of any Records related to the Drug Substance, Products, Transferred
Assets, and Assumed Liabilities for its own corporate records, provided that the retention shall be subject to the terms of Section
9.1 and this Section 9.12.

 

9.13
Cooperation in Litigation and Investigations.
Except as set forth in any Ancillary Agreement, from the Closing Date and until three (3) years from the Closing Date, Purchaser and
Novartis shall reasonably cooperate with each other in the defense or prosecution of any claim, action, proceeding, examination, or audit
against or by either Party relating to or arising out of the Products (other than any claim, action, proceeding, examination, or audit
between Purchaser and Novartis or their respective Affiliates arising out of the transactions contemplated hereby or by the Ancillary
Agreements). In connection therewith, and except as set forth in any Ancillary Agreement, from and after the Closing Date, each of Novartis
and Purchaser shall make available to the other during normal business hours and upon reasonable prior written notice, but without unreasonably
disrupting its business, all records relating exclusively to the Drug Substance, the Products, the Transferred Assets, the Assumed Liabilities,
or the Licensed IP held by it and reasonably necessary to permit the defense or investigation of any such any claim, action, proceeding,
examination, or audit (other than any claim, action, proceeding, examination, or audit between Purchaser and Novartis or their respective
Affiliates arising out of the transactions contemplated hereby or by the Ancillary Agreements, with respect to which applicable rules
of discovery shall apply), and shall preserve and retain all such records pursuant to Section 9.11; provided, that neither
Party shall be required to make available such documents if such disclosure could, in such Party’s reasonable discretion, (a) violate
applicable Law or any binding agreement, provided, that such Party uses reasonable best efforts to obtain waivers thereof, (b)
jeopardize any attorney/client privilege or other established legal privilege, or (c) disclose any trade secrets. The Party requesting
such cooperation shall pay the reasonable out-of-pocket costs and expenses of providing such cooperation (including legal fees and disbursements)
incurred by the Party providing such cooperation and by its Representatives, and any applicable Taxes in connection therewith.

 

    	26

     

    

 

9.14
Further Assurances. Subject to the terms and
conditions of this Agreement and the Ancillary Agreements, Purchaser and Novartis shall use commercially reasonable efforts to take,
or cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable under applicable Law to consummate
the transactions contemplated by this Agreement and the Ancillary Agreements. Novartis and Purchaser agree to execute and deliver such
other documents, certificates, agreements, and other writings and to take such other actions as may be reasonably necessary or desirable
in order to consummate or implement expeditiously the transactions contemplated by this Agreement. In furtherance of the foregoing, Purchaser
agrees to provide such assurances as to financial capability, resources, and creditworthiness as may be reasonably requested by any Governmental
Entity or Third Party whose consent or approval is sought hereunder. 

 

ARTICLE
10 

INDEMNIFICATION; SURVIVAL

 

10.1
Survival. The agreements and covenants to be
performed prior to Closing by Novartis and representations and warranties made by Novartis contained in this Agreement, other than the
Novartis Fundamental Representations, each shall survive the Closing until the date that is eighteen (18) months after the Closing Date.
The agreements and covenants to be performed prior to Closing by Purchaser and representations and warranties made by Purchaser contained
in this Agreement, other than the Purchaser Fundamental Representations, shall survive the Closing until the date that is eighteen (18)
months after the Closing Date. The Novartis Fundamental Representations and Purchaser Fundamental Representations shall survive the Closing
until the expiration of the applicable statute of limitations. The covenants and agreements of the Parties contained in this Agreement
that are to be performed at or following the Closing shall survive the Closing until fully performed. Upon expiration of the applicable
survival period, no indemnification of other claim may be brought by a Party alleging misrepresentation or breach of the applicable representation,
warranty, covenant, or agreement, unless prior to the expiration of such applicable survival period the claiming Party shall have provided
a written notice to the other Party describing such alleged breach or misrepresentation with reasonable specificity.

 

    	27

     

    

 

10.2
Indemnification by Novartis. Subject to the limitations
set forth elsewhere in this ARTICLE 10, from and after the Closing, Novartis shall indemnify, defend, and hold harmless Purchaser
and its Affiliates and their respective officers, directors, and employees (collectively, the “Purchaser Indemnified Parties”)
from and against any Losses suffered or incurred by the Purchaser Indemnified Parties to the extent that such Losses are arising out
of or resulting from the following:

 

(a)
the inaccuracy or breach of any representation or warranty
made by Novartis contained in this Agreement or in any Ancillary Agreement or in any certificate or other instrument delivered by Novartis
or any of its Affiliates pursuant to this Agreement or any Ancillary Agreement;

 

(b)
the breach of or failure to perform any covenant or
agreement by Novartis or any of its Affiliates contained in this Agreement or in any Ancillary Agreement; or

 

(c)
any Excluded Asset or any Excluded Liabilities.

 

10.3
Indemnification by Purchaser. Subject to the
limitations set forth elsewhere in this ARTICLE 10, from and after the Closing, Purchaser shall indemnify, defend, and hold harmless
Novartis and its Affiliates and their respective officers, directors, and employees (collectively, the “Novartis Indemnified
Parties”) from and against any Losses suffered or incurred by the Novartis Indemnified Parties to the extent that such Losses
are arising out of or resulting from the following:

 

(a)
the inaccuracy or breach of any representation or warranty
made by Purchaser contained in this Agreement or in any Ancillary Agreement or in any certificate or other instrument delivered by Purchaser
or any of its Affiliates pursuant to this Agreement or any Ancillary Agreement;

 

(b)
the breach of or failure to perform any covenant or
agreement by Purchaser or any of its Affiliates contained in this Agreement or in any Ancillary Agreement;

 

(c)
any and all Assumed Liabilities; or

 

(d)
any Transfer Taxes.

 

10.4
Limitations on Amounts of Losses. Notwithstanding
anything herein to the contrary:

 

(a)
The maximum aggregate liability of Novartis for Losses
pursuant to Section 10.2(a) and Section 10.2(b) shall be limited to $1,000,000 (one million Dollars); provided,
however, that the foregoing limitation on liability shall not apply to Losses pursuant to Section 10.2(a) in respect of
Novartis Fundamental Representations, for which the maximum aggregate liability of Novartis for Losses shall not exceed the sum of the
Purchase Price.

 

(b)
The maximum aggregate liability of Purchaser for Losses
pursuant to Section 10.3(a) and Section 10.3(b) shall not exceed the sum of the Purchase Price.

 

(c)
Novartis shall not be liable for Losses resulting from
any individual misrepresentation or breach of representation or warranty (each, a “Warranty Breach”) pursuant to Section
10.2(a), unless the aggregate amount of Losses with respect to any such individual Warranty Breach exceeds $150,000 (one hundred
and fifty thousand Dollars) (each, a “Qualifying Loss”); and for any Qualifying Loss unless the aggregate amount of
all Qualifying Losses exceeds $500,000 (five hundred thousand Dollars), in which case the liable Party shall be liable only to the extent
of that excess; provided, however, that the limitations on liability in this Section 10.4(c) shall not apply to
Losses pursuant to Section 10.2(a) in respect of Novartis Fundamental Representations.

 

    	28

     

    

 

(d)
Notwithstanding anything in this Agreement to the contrary,
with respect to any indemnification obligation hereunder arising under any Ancillary Agreement, such indemnification obligation shall
be subject to any applicable limitation on liability set forth in such Ancillary Agreement.

 

10.5
Other Limitations on Indemnification. Notwithstanding
anything herein to the contrary:

 

(a)
All Losses for which any Indemnified Party would otherwise
be entitled to indemnification under this ARTICLE 10 shall be reduced by the amount of insurance proceeds, indemnification payments,
and other Third-Party recoveries to which such Indemnified Party actually receives (less any reasonable costs and expenses, including
the aggregate cost of pursuing any related insurance claims in obtaining such amounts) in respect of any Losses incurred by such Indemnified
Party. In the event any Indemnified Party is entitled to any insurance proceeds, indemnity payments, or any Third-Party recoveries in
respect of any Losses for which such Indemnified Party is entitled to indemnification pursuant to this ARTICLE 10, such Indemnified
Party shall use commercially reasonable efforts to obtain, receive, or realize such proceeds, payments, or recoveries. In the event that
any such insurance proceeds, indemnity payments, or other Third-Party recoveries are realized by an Indemnified Party subsequent to receipt
by such Indemnified Party of any indemnification payment hereunder in respect of the claims to which such insurance proceeds, indemnity
payments, or other Third-Party recoveries relate, appropriate refunds shall be made promptly by the relevant Indemnified Parties for
such reduction in Losses for which the Indemnified Party was indemnified prior to the realization of reduction of such Losses.

 

(b)
For purposes of this ARTICLE 10, any inaccuracy
in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other
similar qualification contained in or otherwise applicable to such representation or warranty.

 

10.6
Procedures.

 

(a)
A claim for indemnification for any matter not involving
a Third-Party Claim may be asserted by written notice to the Party from whom indemnification is sought.

 

(b)
Promptly after a Person entitled to indemnification
hereunder (the “Indemnified Party”) has received notice or has knowledge of any Third-Party claim, demand, action
or proceeding, or threatened claim, demand, action or proceeding (a “Third-Party Claim”) which could result in a Loss
for which such Party may be entitled to indemnification under this ARTICLE 10, the Indemnified Party shall promptly deliver to
the Party against whom indemnification is sought under this ARTICLE 10 (the “Indemnifying Party”) written notice
of such Third-Party Claim (the “Claim Notice”), which Claim Notice shall include, to the extent known, the nature
and basis of such Third-Party Claim, the basis for indemnification hereunder, and the amount in dispute under such Third-Party Claim;
provided, however, that the failure of the Indemnified Party to provide the Claim Notice shall not release or waive the
Indemnifying Party from its obligations to the Indemnified Party under this ARTICLE 10 except to the extent that the Indemnifying
Party is actually prejudiced as a result of such failure.

 

    	29

     

    

 

(c)
Following receipt of the Claim Notice, the Indemnifying
Party may elect at any time to assume and thereafter conduct the defense and settlement, of any Third-Party Claim subject to any such
indemnification claim with counsel of the Indemnifying Party’s choice and to settle or compromise any such Third-Party Claim, and
the Indemnified Party shall cooperate in all respects with the conduct of such defense by the Indemnifying Party and/or the settlement
of such Third-Party Claim by the Indemnifying Party; provided, however, that the Indemnifying Party will not approve of
the entry of any judgment or enter into any settlement or compromise with respect to the Third-Party Claim without the Indemnified Party’s
prior written approval (which shall not be unreasonably withheld, conditioned, or delayed), unless the terms of such settlement provide
for a complete release of the claims that are the subject of such action, claim, or proceeding in favor of the Indemnified Party. Notwithstanding
the foregoing, the Indemnified Party shall have the right to control the defense of, and the Indemnifying Party shall not be entitled
to assume the defense of, any Third-Party Claim that seeks relief other than monetary damages against the Indemnified Party and that
the Indemnified Party reasonably determines, after conferring with its outside counsel, cannot be separated from any related claim for
money damages.

 

(d)
The Parties agree to cooperate fully in connection with
the defense, negotiation, or settlement of any claim for indemnification arising from a Third-Party Claim. Such cooperation will include
the retention and, upon the request of the party defending, negotiating or settling the claim, the provision to such party of records
and information which are reasonably relevant to such Third-Party Claim, and making employees and other Representatives reasonably available
on a mutually convenient basis to provide additional information and explanation of any materials provided hereunder.

 

(e)
If the Indemnifying Party fails or refuses to undertake
the defense of such Third-Party Claim within sixty (60) calendar days after the claim for indemnification has been tendered to the Indemnifying
Party by the Indemnified Party, pursuant to and in accordance with Section 10.6(c), or if the Indemnifying Party later fails to
conduct in good faith the defense or withdraws from such defense, the Indemnified Party shall have the right to (i) undertake the defense
of such claim with counsel of its own choosing, with the Indemnifying Party being responsible for the reasonable costs and expenses of
such defense as Losses hereunder if and to the extent that such claim is determined to be a claim for which such Indemnified Party is
entitled to be defended, indemnified, held harmless or reimbursed under this ARTICLE 10, and (ii) settle or compromise, or attempt
to settle or compromise, the Third-Party Claim; provided, however, that the Indemnified Party shall not settle or compromise
such Third-Party Claim without the Indemnifying Party’s prior written consent (which shall not be unreasonably withheld, conditioned,
or delayed).

 

    	30

     

    

 

10.7
Tax Treatment. To the extent permitted by applicable
Law, Purchaser and Novartis agree to treat any payments made pursuant to the indemnification provisions of this Agreement as an adjustment
to the Purchase Price for Tax purposes.

 

10.8
Exclusive Remedy. Except in respect of Fraud,
from and after the Closing, the indemnification provisions contained in this ARTICLE 10 will constitute the sole and exclusive
recourse and remedy of the Parties with respect to any claim arising from this Agreement or the transactions contemplated hereby, whether
by contract, tort or otherwise. Notwithstanding the foregoing, the provisions of this ARTICLE 10 will not restrict the right of
any Party to seek specific performance or other equitable remedies in connections with any breach of any of the covenants contained in
this Agreement. The Parties agree that the provisions in this Agreement relating to indemnification, and the limits imposed on the Indemnified
Parties’ remedies with respect to this Agreement and the transactions contemplated hereby were specifically bargained for between
sophisticated parties and were specifically taken into account in the determination of the amounts to be paid hereunder. 

 

10.9
No Setoff Rights. Neither Party shall have any
right of setoff of any amounts due and payable, or any Liabilities arising, under this Agreement against any other amounts due and payable
under this Agreement or any amounts due and payable, or any Liabilities arising, under any Ancillary Agreement. The payment obligations
under each of this Agreement and the Ancillary Agreements remain independent obligations of each Party, irrespective of any amounts owed
to any other Party under this Agreement or the respective Ancillary Agreements.

 

ARTICLE
11 

MISCELLANEOUS

 

11.1
Expenses. Except as expressly provided herein
or in any Ancillary Agreement, all costs and expenses incurred in connection with this Agreement, the Ancillary Agreements, and the transactions
contemplated hereby and thereby shall be paid by the Party incurring such costs and expenses. 

 

11.2
Waiver and Amendment. The failure of any Party
to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of
that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective
unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified
except by an instrument in writing signed by each of the Parties.

 

11.3
Entire Agreement. This Agreement, including the
annexes, schedules, and exhibits attached hereto which are deemed for all purposes to be part of this Agreement, the Ancillary Agreements,
and any other documents delivered pursuant to this Agreement and the Ancillary Agreements, constitute the entire agreement among the
Parties with respect to the subject matter hereof and thereof and supersedes all prior communications, representations, agreements, and
understandings, both oral and written, among the Parties with respect to the subject matter hereof and thereof. There are no contracts,
agreements, representations, warranties, promises, covenants, or arrangements among the Parties hereto with respect to the transactions
contemplated hereby, other than those expressly set forth in this Agreement, the Ancillary Agreements, and any other documents delivered
pursuant to this Agreement and the Ancillary Agreements.

 

    	31

     

    

 

11.4
Headings. The headings contained in this Agreement
are intended solely for convenience and shall not affect the rights of the Parties.

 

11.5
Notices. All notices, consents, waivers and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of
actual receipt, or (a) personal delivery to the Party to be notified, (b) upon receipt of delivery confirmation, if sent by electronic
mail, or (c) one (1) Business Day (if recipient is located in the country in which sender is located) or two (2) Business Days (if recipient
is located in a country other than the country in which send sender is located) after deposit with an internationally recognized overnight
courier, freight prepaid, specifying next Business Day delivery, providing proof of delivery. The recipient shall promptly confirm its
receipt of any such electronic mail. All communications shall be sent to the respective Parties as set forth below or to such other Person
or address as any Party shall specify by notice in writing to the other Party.

 

If
to Novartis:

 

Novartis
Technology LLC

1
Health Plaza

East
Hanover, NJ 07936

Attention:     Head of BD&L, Novartis Pharma

Email:

 

If
to Purchaser:

 

Harrow
Health, Inc.

102
Woodmont Blvd.

Suite
610

Nashville,
TN 37205

Attention:Andrew
Boll

Email:

 

With
a copy to:

 

Perkins
Coie LLP

11452
El Camino Real, Suite 300

San
Diego, CA 92130-2080

Attention:Matthew
Ferry

Email:

 

    	32

     

    

 

11.6
Binding Effect; Assignment. This Agreement shall
be binding upon and shall inure to the benefit of the Parties and their permitted successors and assigns. No Party may assign or delegate,
by operation of law or otherwise, all or any portion of its rights, obligations, or liabilities under this Agreement without the prior
written consent of the other Party; provided, however, that: (a) Purchaser may assign its rights and obligations under
this Agreement or any part hereof to one or more of its Affiliates without the consent of Novartis; and (b) Novartis may (i) assign its
rights and obligations under this Agreement or any part hereof to one or more of its Affiliates without the consent of Purchaser; and
(ii) assign this Agreement in its entirety to a successor to all or substantially all of its business or assets to which this Agreement
relates. Notwithstanding the foregoing, at any time after the end of the Phase 1 Period, Purchaser may assign its rights and obligations
under ARTICLE 9 of this Agreement to one or more of its Affiliates or to a Third Party successor in interest to all or substantially
all of Purchaser’s business or assets related to one or more of Maxitrol, Iopidine and Moxeza, in each case, without the consent
of Novartis. Any permitted assignee shall assume all obligations of its assignor under this Agreement (or related to the assigned portion
in the case of a partial assignment), and no permitted assignment shall relieve the assignor of liability hereunder. Any purported assignment
without such prior written consent shall be void and of no force or effect. 

 

11.7
No Third Party Beneficiary. Except for the rights
of the Novartis Indemnified Parties and the Purchaser Indemnified Parties under ARTICLE 10, nothing in this Agreement shall confer
any rights, remedies or claims upon any Person or entity not a Party or a permitted assignee of a Party.

 

11.8
Counterparts. This Agreement may be signed in
any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such
counterparts together shall be deemed an original of this Agreement. Delivery of an executed counterpart of this Agreement by facsimile
transmission or by electronic mail in portable document format (.pdf) shall be as effective as delivery of a manually executed counterpart
hereof.

 

11.9
Force Majeure. If and to the extent that either
Party is prevented or delayed by Force Majeure from performing any of its obligations under this Agreement and promptly so notifies in
writing the other Party, specifying the matters constituting Force Majeure together with such evidence in verification thereof as it
can reasonably provide and specifying the period for which it is estimated that the prevention or delay will continue, then the Party
so affected shall be relieved of liability to the other for failure to perform or for delay in performing such obligations (as the case
may be), but shall nevertheless use its commercially reasonable efforts to resume full performance thereof.

 

11.10
Governing Law and Jurisdiction. This Agreement
and any claim or controversy hereunder shall be governed by and construed under the Laws of the State of New York, without giving effect
to the conflict of laws provision thereof. Any claim or dispute arising out of or relating to this Agreement shall be subject to the
exclusive jurisdiction of the United States District Court for the Southern District of New York, so long as it shall have subject matter
jurisdiction over such claim or dispute and otherwise the state courts located in the State of New York. Each Party irrevocably agrees
and consents to the jurisdiction of the courts set forth in this Section 11.10 and waives any objection it may have to the venue
of such courts, including with respect to the convenience of the forum and jurisdiction.

 

    	33

     

    

 

11.11
WAIVER OF JURY TRIAL. EACH OF THE PARTIES HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
ANY LEGAL PROCEEDING (WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT, ANY ANCILLARY AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY, OR THE NEGOTIATION, ADMINISTRATION, PERFORMANCE,
OR ENFORCEMENT HEREOF OR THEREOF. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT, OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES
THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION.

 

11.12
Severability. If any term, provision, agreement,
covenant, or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the remainder
of the terms, provisions, agreements, covenants, and restrictions of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired, or invalidated. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement
so as to affect the original intent of the Parties as closely as possible in a reasonably acceptable manner so that the transactions
contemplated hereby may be consummated as originally contemplated to the fullest extent possible.

 

11.13
Specific Performance. The Parties agree that
irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the
Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at
law or in equity. It is therefore agreed that the Parties shall be entitled to seek a temporary, preliminary, and/or permanent injunction
or injunctions to prevent breaches of this Agreement and to enforce specifically the performance of the terms of this Agreement, without
posting any bond or other undertaking, in addition to any other remedy to which they are entitled at law or in equity.

 

11.14
Relationship of the Parties. Nothing contained
in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between Novartis and Purchaser,
or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions
contemplated hereby, as a partnership for any Tax purposes. Each Party shall act solely as an independent contractor, and nothing in
this Agreement shall be construed to give any Party the power or authority to act for, bind or commit the other.

 

11.15
Extension to Affiliates. Novartis shall have
the right to extend the rights, immunities, and obligations granted in this Agreement to one or more of its Affiliates. All applicable
terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent
as such terms and provisions apply to Novartis. Novartis shall remain primarily liable for any acts or omissions of its Affiliates.

 

    	34

     

    

 

11.16
English Language. This Agreement is written and
executed in the English language. Any translation into any other language shall not be an official version of this Agreement and in the
event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 

 

11.17
Construction. The Parties agree that the terms
and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in
favor of or against any Party by reason of the extent to which any Party participated in its preparation.

 

11.18
No Recourse Against Nonparty Affiliates. All
claims, obligations, liabilities, or causes of action (whether in contract or in tort, in law or in equity, or granted by statute) that
may be based upon, in respect of, arise under, out or by reason of, be connected with, or relate in any manner to this Agreement, or
the negotiation, execution, or performance of this Agreement (including any representation or warranty made in, in connection with, or
as an inducement to, this Agreement), may be made only against (and are those solely of) the entities that are expressly identified as
Parties in the preamble to this Agreement (or their permitted assignees) (“Contracting Party”). No Person who is not
a Contracting Party, including any director, officer, employee, incorporator, member, partner, manager, unitholder, stockholder, Affiliate,
agent, attorney, or representative of, and any financial advisor or lender to, any Contracting Party, or any director, officer, employee,
incorporator, member, partner, manager, unitholder, stockholder, Affiliate, agent, attorney, or representative of, and any financial
advisor or lender to, any of the foregoing (“Nonparty Affiliates”), shall have any liability (whether in contract
or in tort, in law or in equity, or granted by statute) for any claims, causes of action, obligations, or liabilities arising under,
out of, in connection with, or related in any manner to this Agreement or based on, in respect of, or by reason of this Agreement or
its negotiation, execution, performance, or breach; and, to the maximum extent permitted by Law, each Contracting Party hereby waives
and releases all such liabilities, claims, causes of action, and obligations against any such Nonparty Affiliates. Without limiting the
foregoing, to the maximum extent permitted by Law, (a) each Contracting Party hereby waives and releases any and all rights, claims,
demands, or causes of action that may otherwise be available at law or in equity, or granted by statute, to avoid or disregard the entity
form of a Contracting Party or otherwise impose liability of a Contracting Party on any Nonparty Affiliate, whether granted by statute
or based on theories of equity, agency, control, instrumentality, alter ego, domination, sham, single business enterprise, piercing the
veil, unfairness, undercapitalization, or otherwise; and (b) each Contracting Party disclaims any reliance upon any Nonparty Affiliates
with respect to the performance of this Agreement or any representation or warranty made in, in connection with, or as an inducement
to this Agreement.

 

11.19
Novartis Disclosure Schedule. All capitalized
terms not defined in the Novartis Disclosure Schedule shall have the meanings ascribed to them in this Agreement. The representations,
warranties, covenants, and agreements of Novartis set forth in this Agreement are made and given subject to, and are qualified by, the
Novartis Disclosure Schedule. Any disclosure set forth in one section or subsection of the Novartis Disclosure Schedule shall be deemed
to apply to and qualify the section or subsection of this Agreement to which it corresponds in number and each other section or subsection
of this Agreement to the extent that it is reasonably apparent on its face that such information is relevant to such other section or
subsection. The Novartis Disclosure Schedule may include brief descriptions or summaries of certain agreements and instruments. The descriptions
or summaries do not purport to be comprehensive and are qualified in their entirety by reference to the text of the documents described
to the extent such text has been provided to Purchaser prior to the date hereof. No disclosure set forth in the Novartis Disclosure Schedule
relating to any possible breach or violation of any contract or Law shall be construed as an admission or indication that any such breach
or violation exists or has actually occurred. The inclusion of any information in the Novartis Disclosure Schedule shall not be deemed
to be an admission or acknowledgment that such information (a) is required by the terms of this Agreement to be disclosed, (b) is material,
(c) has resulted in or would result in a Material Adverse Effect, or (d) that such information creates a measure of materiality for purposes
of this Agreement. 

 

[Remainder
of page intentionally left blank]

 

    	35

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement as of the date first above written.

 

	 	PURCHASER:
	 	 
	 	HARROW
    HEALTH, INC.
	 	 	 
	 	By:
    	/s/
    Mark L. Baum
	 	Name:	Mark
    L. Baum
	 	Title:	CEO

 

[Signature Page to Asset Purchase Agreement]

 

    	 

     

    

 

	 	NOVARTIS:
	 	 
	 	NOVARTIS
    TECHNOLOGY LLC
	 	 	 
	 	By:
    	/s/
    Michael Stewart
	 	Name:	Michael
    Stewart
	 	Title:	Head
    Legal, Strategic Transactions
	 	 	 
	 	NOVARTIS
    OPHTHALMICS AG
	 	 	 
	 	By:	/s/
    Sven Werner
	 	Name:	Sven
    Werner
	 	Title:
    	Gl.
    BD&L Head Divestment and Outlicensing
	 	 	 
	 	By:
    	/s/
    Eric Careau
	 	Name:	Eric
    Careau
	 	Title:
    	Gl.
    BDL Divestment

 

[Signature Page to Asset Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]